Medical decision making - a personalized approach by Wei, Xin





























In Partial Fulfillment 
of the Requirements for the Degree 
Doctor of Philosophy in the 













Copyright © 2018 by Xin Wei 





























Dr. Eva K. Lee, Advisor 
H. Milton Stewart School of Industrial 
and Systems Engineering 
Georgia Institute of Technology 
 Dr. Andy Sun 
H. Milton Stewart School of Industrial 
and Systems Engineering 




Dr. Edwin Romeijn 
H. Milton Stewart School of Industrial 
and Systems Engineering 
Georgia Institute of Technology 
 Dr. Alexander Quarshie 
Clinical Research Center 




Dr. Yajun Mei 
H. Milton Stewart School of Industrial 
and Systems Engineering 
Georgia Institute of Technology 
  
   




  I would like to express my sincere appreciation to my advisor, Dr. Eva Lee, for her 
guidance, understanding and financial support for my PhD study. The accomplishment of 
this dissertation would have been impossible without her inspiration and instruction. 
 
I would like to thank Dr. Edwin Romeijn, Dr. Yajun Mei, Dr. Andy Sun, and Dr. 
Alexander Quarshie for serving on my dissertation committee. I am particularly thankful 
to their valuable comments and feedback on my work. 
 
I would like to acknowledge National Science Foundation, the National Institutes 
of Health, and the Centers for Disease Control and Prevention for their funding support. 
 
I would like to acknowledge ISyE faculties for their excellent teaching, ISyE staffs 
for their administrative support, and current and former fellow students for their help in my 
academic and personal life. Specially, I want to thank the members in the Center for 
Operations Research in Medicine and Healthcare for their support of my research. 
 
I also want to thank all my friends in Atlanta who accompanied with me during my 
PhD study. I really cherish the friendship and will remember all the happiness for my life. 
At last, I want to thank my parent for their endless love. I know you are always my 




TABLE OF CONTENTS 
ACKNOWLEDGEMENTS iii 
LIST OF TABLES vii 
LIST OF FIGURES ix 
SUMMARY xi 
CHAPTER 
I INTRODUCTION 1 
II PREDICTING TREATMENT DOSE-EFFECT USING SELF-MONITORED 
BLOOD GLUCOSE DATA FOR DIABETES MANAGEMENT 5 
2.1 Introduction 5 
2.2 Method 8 
2.2.1 The PK/PD drug effect model 8 
2.2.2 Treatment effect model combining disease progression 13 
2.2.3 Fitting the treatment effect model by SMBG data 16 
2.3 Result and discussion 17 
2.3.1 Establishing the predictive treatment effect parameters 18 
 v 
2.3.2 Model validation and comparison 19 
2.4 Conclusion 24 
III DOSE-EFFECT EVIDENCE-BASED PERSONALIZED TREATMENT 
PLANNING FOR MANAGING GESTATIONAL DIABETES MELLITUS 26 
3.1 Introduction 26 
3.2 Method 29 
3.2.1 The treatment effect model 29 
3.2.2 Dose optimization model 30 
3.3 Result and discussion 34 
                  3.4 Conclusion 40 
IV MULTI-OBJECTIVE DIRECT APERTURE OPTIMIZATION MODEL FOR 
RADIOTHERAPY PLANNING 42 
4.1 Introduction 42 
4.1.1 Background 42 
4.1.2 Treatment planning 48 
4.2 Methods to advance treatment planning and applications to Cyberknife 56 
4.2.1 Isocenter selection 56 
 vi 
4.2.2 Multi-objective direct aperture optimization 62 
4.2.3 Column generation 71 
                        4.2.4 Beam selection 81 
4.3 Computational result 84 
4.3.1 Patient cases and clinical guidelines 84 
4.3.2 Beams and initial apertures 89 
4.3.3 Optimization result 92 








LIST OF TABLES 
Table 3.1: Parameters and decision variables in dose optimization model 32 
Table 3.2: Selected characteristics of patient information 35 
Table 3.3: Comparison of the dosage level of the optimized regimen versus the 
original clinical regimen in a 10-week treatment horizon 
37 
Table 4.1: Structure size of each prostate case 85 
Table 4.2: Treatment objectives for prostate cases (36.25Gy/5Fx) 85 
Table 4.3: Structure size of each lung case 86 
Table 4.4: Treatment objectives for lung cases (50Gy/5Fx) 86 
Table 4.5: Structure size and treatment objectives for Intracranial 1 (12Gy/1Fx) 87 
Table 4.6: Structure size and treatment objectives for Intracranial 2 (25Gy/5Fx) 88 
Table 4.7: Structure size and treatment objectives for Intracranial 3 (25Gy/5Fx) 88 
Table 4.8: Structure size and treatment objectives for Intracranial 4 (25Gy/5Fx) 88 
Table 4.9: Structure size and treatment objectives for Intracranial 5 (20Gy/1Fx) 89 
Table 4.10: Size of beam and initial aperture set 91 
 viii 
Table 4.11: Conformity index(CI) of the plan after beam selection with different 
𝐵𝑚𝑎𝑥 
97 
Table 4.12: Plan quality of the optimal solution for 5 prostate cases 98 
Table 4.13: Plan quality of the optimal solution for 5 lung cases 99 
Table 4.14: Plan quality of the optimal solution for intracranial case 1 99 
Table 4.15: Plan quality of the optimal solution for intracranial case 2 100 
Table 4.16: Plan quality of the optimal solution for intracranial case 3 100 
Table 4.17: Plan quality of the optimal solution for intracranial case 4 101 
Table 4.18: Plan quality of the optimal solution for intracranial case 5 101 
Table 4.19: Computational statistics of the LLDAO+BS algorithm for 15 cases 104 




LIST OF FIGURES 
Figure 2.1: Selected characteristics of patient information 10 
Figure 2.2: Comparison of the dosage level of the optimized regimen versus the 
original clinical regimen in a 10-week treatment horizon 
13 
Figure 2.3: Blood glucose level recorded before breakfast of patient 1 20 
Figure 2.4: Result of fitting the treatment effect model for patient 1 in all 4 
phases 
22 
Figure 2.5: Result of fitting the AR(2) model for patient 1 in all 4 phases 24 
Figure 3.1: Decision process for the treatment of pregnant women with 
gestational diabetes 
31 
Figure 3.2: Comparison of original regimen vs. optimized regimen of patient 5 36 
Figure 3.3: Box-Whisker plot of the reduction of total positive deviation over 
the entire treatment horizon of each phase 
39 
Figure 3.4: The efficient frontier of the two-objective dose optimization model 40 
Figure 4.1: LINAC System and Multi-leaf collimator 45 
Figure 4.2: The DICOM image showing a case of prostate cancer 48 
Figure 4.3: Fluence map optimization and leaf sequencing 49 
 x 
Figure 4.4: The tumor shape of a schwannoma case 59 
Figure 4.5: The fitted voxel vs. slice curve 60 
Figure 4.6: The candidate locations of ISOFLP and its optimal solution 61 
Figure 4.7: The process map of LLDAO 65 
Figure 4.8: A prostate case solved by traditional two-step method 72 
Figure 4.9: Dose degradation of aperture-based dose calculation 73 
Figure 4.10a: Dual Sum Map (DSM) 79 
Figure 4.10b: Dual Fluence Map (DFM) with d− = 0 and d+ = 2 80 
Figure 4.10c: An aperture(shaded) created by leaf sequencing algorithm 80 
Figure 4.10d: Final aperture with shape corrected to satisfy MLC constraints 80 
Figure 4.11: Process map of LLDAO with beam selection 83 
Figure 4.12: Candidate non-coplanar beams in CT space 90 
Figure 4.13: Initial apertures are created to cover PTV projection subtracted by 
OAR projection 
91 




Figure 4.14b: Maximize lower 5% CVaR of PTV dose distribution to ensure 
95% of PTV voxels have dose greater than 36.25Gy 
94 
Figure 4.14c: Minimize dose to Shell_2mm structure to reduce conformity index 94 
Figure 4.14d: Minimize dose to Shell_2mm with only 20 beams allowed to be 
selected 
95 
Figure 4.14e: Minimize mean dose of bladder using 20 beams selected by beam 
angle optimization 
95 
Figure 4.14f: Minimize mean dose of rectum using 20 beams selected by beam 
angle optimization 
96 
Figure 4.14g: Minimize total MU with the minimum MU allowed for an open 
aperture set as 50 
96 
Figure 4.15: Comparison of dose conformity between one-isocenter plan and 
two-isocenter plan for intracranial case 1 
102 
Figure 4.16: Efficient Frontier of the multi-objective direct aperture 
optimization 
104 






Medical decision making seeks to explain how physicians and patients routinely make 
decisions and identify both barriers and facilitators of effective decision making. In real 
practice, patients are different in their personal characteristics, drug response and treatment 
compliance. Furthermore, physicians are still depending on trial-and-error approach to treat 
patients. In this dissertation, we focus on developing mathematical foundation and 
computational tools that guide physicians (and patients) to make good decisions.  
Specifically, we developed models that estimate the patient’s personalized response to 
treatment and optimized the treatment to achieve best possible outcome.   
The first topic of this dissertation focuses on the management of diabetes mellitus. A 
pharmacokinetic and pharmacodynamics (PK/PD) drug effect model was developed to 
characterize the dose response of patients receiving anti-diabetic drug therapy. A linear 
disease progression model was combined with a drug effect model to characterize the trend 
of blood glucose level over time. The personalized dose response was estimated using the 
daily self-monitored blood glucose (SMBG) data recorded by the patient during the first 4 
weeks of diabetes treatment. We tested the model on patients with gestational diabetes 
mellitus (GDM). Compared to the standard autoregression model, our treatment effect 
model gives better long-term prediction on the trend of blood glucose level. It offers the 
first predictive treatment-effect model which relates drug dose to drug effect. 
We utilized the individualized treatment effect model and result to design a personalized 
treatment planning model to optimize the dosing strategy for each patient. A mixed-integer 
program was developed to optimize the drug prescription for each patient based on his/her 
 xiii 
own personalized dose response and disease progression. In a retrospective study, we 
optimized the dose regimen using our model. Compared to the original dose regimen that 
is used to treat these patients in the clinic, the optimized dose regimen uses smaller or equal 
amount of drug but achieve better glycemic control.  
The second topic focuses on the optimization of external radiation therapy. We first 
proposed a math programming formulation to the isocenter selection problem and 
developed a fast heuristic approach to determine the number and location of the isocenters 
of the radiation beams. Second, we proposed a multi-objective direct aperture and beam-
angle model that optimizes each treatment objective based on its clinical priority. The 
objectives are determined by a patient’s personalized need. To solve these optimization 
problems, we developed an efficient heuristic column generation algorithm that creates 
apertures without using any dose information. Finally, we incorporated a mixed-integer 
beam selection module into the direct aperture optimization to optimally select beam angles 
from which the radiation is delivered. The test result of three types of patients (lung, 
prostate, and intracranial cancer) shows that our method can create deliverable clinically 
acceptable plans within reasonable time. The resulting plans offer better dose distribution 









Medical science has been greatly enriched during the last three decades. Numerous 
technological innovations have been developed to enable more accurate diagnosis and 
more effective treatment. For example, the human genome project, completed in 2003, has 
greatly benefitted the society and medical science[1]. Understanding the human variation 
can directly translate to human health with the creation of better treatments and 
personalized medicine. This led to extensive clinical and translational research effort in  
advancing early diagnosis and targeted   treatment[2].  The launch of the 10-year-effort to 
create a national electronic medical record (EMR) system by the United State government 
in 2004 helped fuel the medical advance[3]. Clinicians are more eager to adopt and 
leverage data to help them formulate and make decisions that can benefit the patients.  
While these technologies have the potential to greatly improve the health of humans, they 
have also increased the complexity of decision making for healthcare providers and 
policymakers[4]. Specifically, the process of medical decision making, including the 
complex tradeoffs between risks and benefits of diagnosis and treatments, is still lagged 
behind the advances in technology.  
Clinicians began to improve the diagnosis and treatment by bringing tools from other 
disciplines, such as statistics, decision science and computer science. Many mathematical 




outcome. Some of these models seek to explain how physicians and patients routinely make 
decisions and identify both barriers and facilitators of effective decision making. Others 
help guide physicians, patients and healthcare policymakers to make good decisions in 
practice. Among them, methods like simulation, optimization, machine learning have been 
successfully used in real practice[4-7]. 
One of the challenges in medical decision making is the complexity, variability and 
uncertainty that exist in both patients and different treatment methods. Through clinical 
training and residency programs, doctors learn to make their decisions based on personal 
experience. This results in practice variability which may affect the outcome. Clinical 
guidelines, which are summarized from clinical trials, are often population-specific and 
average out the individual variability. An effective treatment for one patient may not 
guarantee the same result for others. Hence, each patient must go through a trial-and-error 
process until the treatment outcome becomes satisfactory. This drives up the cost of 
healthcare and delay expected outcome.  
In this dissertation, we focus on developing mathematical models that target medical 
treatment to personalized characteristics of each patient, which is often called personalized 
medicine (PM). Formally, personalized medicine is defined as a medical procedure that 
separates patients into different groups with medical decisions, practices, interventions 
being tailored to the individual patient based on their predicted response or risk of 
disease[8]. Personalized characteristics, from genetic content to all sorts of personalization 
measures are identified by informatics approaches. Such evidence is then used in diagnosis 




Inspired by this idea, we developed a personalized approach for diabetes management[9-
11]. In chapter II, we derived a mathematical model to characterize the drug effect of 
diabetes patients taking anti-diabetes drugs[10]. The model estimates a patient’s dose 
response and disease progression using his/her daily recorded blood glucose data. It 
provides an accurate long-term prediction on the trend of blood glucose level in the future. 
This work answers a fundamental century-long puzzle in pharmacology on how to predict 
dose effect without using invasive procedures to measure drug concentration in the body.  
In chapter III, such personalized evidence of dose response is utilized within an  
individualized treatment planning model that  optimizes the dose regimen for diabetes[11]. 
Empowered by the accurate drug dose-effect prediction on each patient, the resulting 
optimized dose regimen achieves better glycemic control and uses less drug when 
compared to the original clinical treatment. Chapter II and Chapter III introduce the first-
of-its-kind personalized drug-dose effective predictive treatment planning for diabetes 
management[9]. 
In chapter IV, we discussed the optimization of external radiation therapy treatment 
planning[12-14]. Radiation therapy, which uses ionizing radiation to treat cancers, has long 
employed sophisticated mathematics to help with personalized treatment design. Recently, 
it has become much more efficient by using flexible robotic systems. High-energy and 
precise radiation beams are produced to kill cancerous cells and keep surrounding normal 
tissues safe. A multi-objective model is developed where each clinical objective is 
optimized sequentially based on its clinical priority. Patient’s anatomical structure and 




in optimization. The resulting plans are clinically acceptable with better dose distribution 




















PREDICTING TREATMENT DOSE-EFFECT USING SELF-
MONITORED BLOOD GLUCOSE DATA FOR DIABETES 
MANAGEMENT 
The content of this chapter is based on two manuscripts:  
[9]Eva K. Lee, X.W., Francine Baker-Witt, Michael D. Wright, Alexander Quarshie, 
Outcome-Driven Personalized Treatment Design for Managing Diabetes. Interfaces - The 
Daniel H. Wagner Prize for Excellence in Operations Research Practice. To appear 2018 
[10]Eva K. Lee, X.W., Francine Baker-Witt, Michael D. Wright, Alexander Quarshie, 
Predicting Treatment Dose-effect Using Self-Monitored Blood Glucose Data for Diabetes 




Diabetes is one of the most popular chronic disease, with a devastating impact on the 
affected patients and their families.  As of 2015, approximately 415 million people had 
diabetes worldwide and is one of the top 10 leading cause of death[15]. More than $245 




Patients with diabetes either cannot produce enough insulin or cannot respond properly to 
the insulin produced[17]. High blood glucose level is often observed in diabetic patients 
and increases the risk of the complications such as stroke, diabetic retinopathy and 
glaucoma[18]. Therefore, the management of diabetes focuses on the control of blood 
glucose level within the recommended range. Dietary control and physical activities are 
the most common interventions. If they fail to control the blood glucose level, insulin 
injection or oral anti-diabetic medications will be used. One of the difficulties in diabetes 
management is to estimate the treatment effect on patients receiving insulin or drug 
therapy. Since patients are different in eating habit, dose response and treatment 
compliance, it is hard for clinicians to figure out whether the treatment is effective or not. 
Therefore, clinicians still use trial-and-error approach in prescribing the drug and the 
dosage.  
Many mathematical models are developed to help clinicians address the complexity, 
variability, and uncertainties of diabetes management. Computer simulation models have 
been used to analyze and predict the health outcomes and economic consequences of 
various diabetes therapies[19, 20]. These models focus on predicting the long-term 
treatment effects such as death rate and expected quality-adjusted life years (QALYs). 
Another type of model tries to describe the insulin-glucose dynamics in human body. The 
insulin-glucose dynamics is modeled by a set of ordinary differential equations 
(ODEs)[21]. The minimal model developed by Bergman et al.[22] is one of the first models 
that characterize the change in glucose and insulin concentration after the steady state is 
broken by perturbations (e.g. food intake or insulin injection). These models are commonly 




More elegant models are proposed to capture deterioration of the 𝛽-cells over time, and 
allows more accurate prediction of the time course of glucose and insulin concentrations 
in the long run[23]. The pharmacokinetic/pharmacodynamics (PK/PD) models are 
proposed to study the effects of antidiabetic drugs on insulin-glucose homeostasis[24]. 
These models often treat the body as a system of compartments and assume that the rate of 
transfer between compartments follow first-order or linear kinetics. The drug effect is then 
described by a sigmoid function, which is driven by drug concentrations in the hypothetical 
effect compartment[25]. These models characterize the mechanism of drug action and, in 
practice, are mostly used to estimate the efficacy and toxicity of a drug on its target patients. 
They can also be used to explore the influence of demographic characteristics or the disease 
status and progression on drug effects[26]. However, some studies show that these PK/PD 
models cannot fit all doses simultaneously with a single set of parameters, which suggest 
that they cannot explain the underlying system sufficiently[27]. Advanced statistical 
models are also developed to analyze the dynamic of insulin glucose system and to predict 
blood glucose levels in the near future[28, 29]. Wang et al. developed an autoregressive 
model with time-varying parameters that captures the dynamic of blood glucose level in a 
short period of time. Compared with models with non-time-varying parameters, their 
model gives better prediction on near future blood glucose level based on insulin delivery 
and meal intake[30]. In [31], a data assimilation framework is proposed to combine the 
sparse measurement of glucose regulatory system with a nonlinear mechanism-based 
model in the ICU setting. In a simulation study, the author demonstrated that the model 




these methods, complicated techniques are often needed to account for the high variability 
and missing values of the data, which is common in diabetes management.  
The ability to estimate, predict and control blood glucose level is the most important 
problem in diabetes management. In this chapter, we proposed a treatment effect model 
combining a PK/PD drug effect model and a linear disease progression model. The model 
captures the drug-glucose dynamics and the effect of different drug dosages to the value of 
blood glucose level.  Patient’s personalized characteristics of dose response and disease 
progression are estimated by fitting the treatment effect model to the self-monitored blood 
glucose levels (SMBG). Although self-monitoring has long been accepted as an important 
component of diabetes management, it is still difficult to successfully utilize it in the 
treatment. To our knowledge, this is the first model that use SMBG to draw insights of the 
personalized drug effect and disease progression of the patient. Moreover, compared to the 
descriptive autoregression model, our mechanism-based model gives better forecast on the 
trend of blood glucose level. Therefore, it can be potentially used to optimize the dosing 
strategy of diabetes treatment to improve the outcome. In section 2, we will build the 
treatment effect model. In section 3, we test the model on 14 clinical patients with 








In clinical pharmacology, the intensity of pharmacological effects directly relates to the 
concentration of drug at the effect site[32].  Pharmacokinetic(PK) models characterize the 
time course of drug concentration in the body fluids. The simplest one-compartment model 
is particularly useful for the analysis of drugs that distribute rapidly throughout the body. 
According to first-order kinetics, the plasma drug concentration after a rapid intravenous 
injection is given by 
                                    𝐶𝑝(𝑡) =
𝐷
𝑉
𝑒−𝑘𝑒𝑙∙𝑡                            (2.2.1) 
where 𝐶(𝑡) is the plasma drug concentration at time t, 𝐷 is the injected dose, and 𝑘𝑒𝑙 is the 
apparent first-order elimination rate constant for the drug. Here 𝑉 is the apparent volume 
of distribution which has no direct physiologic meaning but is an indication of the extent 
of drug distribution in the body[33].   
Pharmacodynamics(PD) models characterize the relationship between the drug 
concentration and the drug effect. The effect of a drug present at the site of action is 
determined by that drug’s binding with a receptor and the most commonly used model is 
the sigmoid 𝐸𝑚𝑎𝑥-model, which is of the form: 





𝑛  (2.2.2) 
where 𝐸𝑚𝑎𝑥 is the maximum effect, 𝐶𝑒 is the concentration of the drug at the effect site, 
𝐸𝐶50  is the concentration that produces half of the maximal effect, and 𝑛 is the shape 
factor.  Here 𝐸𝐶50 characterizes the potency of the drug in the system and 𝐸𝑚𝑎𝑥 reflects its 




molecules interacting with a receptor and can provide better data fits, it is rarely used in 
practice[32]. 
PK and PD models are linked together through the plasma drug concentration 𝐶𝑝 and the 
effect site drug concentration 𝐶𝑒 . The relationship between plasma and effect site 
concentration may either be constant or change over time. For direct link models, 
equilibrium between both concentrations is assumed to be rapidly achieved and thus their 
ratio is a constant (fig. 2.1a). For indirect link models, however, there is a temporal 
dissociation between the time course of concentration and effect, which is most likely 
caused by the distributional delay between the concentrations in plasma and at the effect 
site. A general approach to characterize this delay is the effect compartment model first 
introduced by Holford and Sheiner[34, 35]. A hypothetical effect-compartment is attached 
to the pharmacokinetic model to describe the concentration at the effect site (fig. 2.1b).  
 
 
Figure 2.1. Direct link vs. indirect link models[32]. Two ways to calculate the effect site drug 
concentration 𝐶  in the drug effect 𝐸𝑚𝑎𝑥 -model. (a) Direct link model uses plasma drug 
concentration 𝐶𝑝 as 𝐶.  (b) Indirect link model uses effect compartment drug concentration  𝐶𝑒 =
𝐶𝑝 ∙ (1 − 𝑒





To see the relationship of  𝐶𝑝 and 𝐶𝑒 in the indirect link models, assume that the drug influx 
into the effect compartment follows a first-order process. Then we have 
                                   
𝑑𝐶𝑒
𝑑𝑡
= 𝑘𝑒𝑞 ∙ (𝐶𝑝 − 𝐶𝑒)  (2.2.3) 
where  𝑘𝑒𝑞 is the equilibration rate constant. Solving this differential equation, we have 
                                           𝐶𝑒(𝑡) = 𝐶𝑝(𝑡) ∙ (1 − 𝑒
−𝑘𝑒𝑞∙𝑡).  (2.2.4) 
Therefore, by substituting (2.2.4) into (2.2.2) and let the shape factor 𝑛 = 1, the drug-
concentration drug-effect relationship can be modeled as 





              (2.2.5) 
Since it is impossible to measure drug concentration frequently, 𝐶𝑝(𝑡) is often replaced by 
its estimation. For example, Frey et al. compensated for the lack of concentration by using 
the area under the curve[36].  




                                              (2.2.6) 
Area under the concentration-time curve (AUC), which is the integration of (2.2.1) from 
zero to infinity represents the total drug exposure over time and is used in computing the 
average drug concentration over a time period. Most drugs are administered periodically 
with sufficient frequency to maintain the presence of drug in the body. For drugs given in 
a fixed dose at a constant dosing interval, they accumulate in the body until a steady-state 




dosing interval will be identical to the concentration at the same time during any other 
dosing interval[33](fig. 2.2). Suppose a drug is administered at dose 𝐷 with dosing interval 
𝜏 for 𝑁 intervals, then the drug concentration at time 𝑁 ∙ 𝜏 + 𝑡 will be  
      𝐶𝑁(𝑡) =
𝐷
𝑉






            (2.2.7) 
So the steady state drug concentration at any time 𝑡 is given by 








 ,      𝑡 𝜖 [0, 𝜏)                      (2.2.8) 
By (2.2.8), we have the following relationship: 
         𝐴𝑈𝐶1











              (2.2.9) 
Therefore, 𝐴𝑈𝐶 during any dosing interval at steady state (𝐴𝑈𝐶𝑠𝑠
0−𝜏
) is the same as the 












 in (2.2.6), we have 













                                  (2.2.10) 




(mg-1). It reflects the drug sensitivity of a patient as the drug will be more effective for 





Figure 2.2. This figure shows the time course of drug concentration after multiple intravenous 
dosing with D = 200 mg; V = 10L; kel = 0.1 min
-1 and τ = 100 min. Since no absorption time is 
considered, the drug concentration will spike suddenly at each drug administration time.  
 
2.2.2 Treatment effect model combining disease progression 
The treatment effect of diabetes management consists of two main parts: disease 
progression and drug effect. Frey et al. proposed a mixture model capturing both parts of 
the diabetes treatment. In their model, the fasting plasma glucose level (FPG) for a patient 
taking an anti-diabetic drug can be represented by  
                                             𝐹𝑃𝐺(𝑡) = 𝐵𝑎𝑠𝑒 + 𝑆(𝑡) −  𝐸(𝑡)                                           (2.2.11) 
where 𝐹𝑃𝐺(𝑡) is the fasting blood glucose at time t, 𝐵𝑎𝑠𝑒 is the predicted baseline level, 
𝑆(𝑡) is the disease progression model, and 𝐸(𝑡) the drug effect model. Since diabetes is a 
progressive disease, patient’s ability to control blood glucose will gradually get worse over 
time. Therefore, the blood glucose level is expected to increase if the patient is left alone 




is  𝑆(𝑡) = 𝛼 ∙ 𝑡 with constant 𝛼. By substituting the PK/PD drug effect model (2.2.10) into 
(2.2.11), the blood glucose level can be represented as 





     (2.2.12) 
where parameters 𝜷 = (𝐵𝑎𝑠𝑒, 𝛼, 𝐸𝑚𝑎𝑥 , 𝑅𝑑, 𝑘𝑒𝑞). 
The behavior of blood glucose level under this model can be divided into three phases 
according to the behavior of the function 𝐵𝐺𝐿(𝜷, 𝑡). Notice that there are two roots of 
𝜕𝐵𝐺𝐿
𝜕𝑡
(𝜷, 𝑡) = 0 , denoted as 0 < 𝑡1 < 𝑡2 . When 𝑡 < 𝑡1 , the blood glucose level will 
gradually increase. Before 𝑡1, drug has not fully taken effect as the equilibrium between 
plasma and effect site drug concentration is not reached. Between 𝑡1 and 𝑡2, the drug effect 
becomes stronger and the blood glucose level start declining. After 𝑡2, the level increases 
again as the disease progression dominates the drug effect again. It means that the drug, 
under current dosage 𝐷, is no longer effective to control the blood glucose level and a dose 
escalation is required. (2.2.12) is also the first to establish the direct relationship between 
drug dosage and the blood glucose level. This model, applied to each patient, can 
potentially help clinicians improve their dosing strategy during the treatment to achieve 
better outcome.  
We are going to implement the treatment effect model to estimate the personalized disease 
progression and dose response of GDM patients and forecast the long-term variations of 
the blood glucose level. Under (2.2.12), the SMBG data collected during the treatment is 




over time. Let 𝐷t  denote the dosage level at time t and {𝐷t, t = 1. . . T} denote the dose 
regimen during the treatment. We can rewrite (2.2.12) as a difference equation 





2    (2.2.13) 





2  is the first-order derivative of 𝐵𝐺𝐿(𝜷, 𝑡)  with 
respect to 𝑡. Therefore, the whole drug-glucose system can be represented as a discrete 
nonlinear state-space system, where the state transition equation is 





2 + ηt,    t = 1. . . T    (2.2.14) 
and the measurement equation is 
                                           𝐿(𝑡) = 𝐵𝐺𝐿(𝜷, 𝑡) + ε𝑡 ,    t = 1. . . T    (2.2.15) 
Here 𝜂𝑡~𝑁(0, 𝑄𝑡) is the Gaussian white noise representing the unmodeled disease process 
and ε𝑡~𝑁(0, 𝐻𝑡) is the Gaussian white noise modeling the blood glucose measurement 
error. The dose regimen {𝐷t, t = 1. . . T} is the control variable and 𝐿(𝑡)  is the SMBG 
readings observed at time 𝑡. Kalman filtering method (KF) is commonly used to fit the 
system (2.2.14) ~ (2.2.15) to the data and forecast future blood glucose levels. The value 
of 𝐵𝐺𝐿(𝜷, 𝑡 + 1) is first predicted based on the value of 𝐿(1). . . 𝐿(𝑡) and is then corrected 
after 𝐿(𝑡 + 1) is observed. However, the standard KF method is only designed to give a 
one-step-ahead prediction and is theoretically difficult to make accurate multi-step 




of the treatment effect, we need to modify (2.2.14) and (2.2.15). In the treatment of 
diabetes, the daily record of blood glucose level is highly stochastic due to various food 
intake. The trend of blood glucose level, which is the moving average of daily blood 
glucose level, tells the efficacy of the treatment. For example, an effective treatment will 
result in the decline of blood glucose level over time. Moreover, a model that can give 
accurate long-term prediction on the trend of blood glucose level can potentially help 
clinicians adjust their dose regimen promptly. Therefore, we use equation (2.2.12) and 
𝐵𝐺𝐿(𝜷, 𝑡) to directly estimate the trend of blood glucose level 





+ ϕ𝑡,    𝑡 = 1. . . 𝑇     (2.2.16) 
where 𝜙𝑡~𝑁(0, Φ𝑡) is the white noise capturing the errors of the trend to the actual blood 
glucose level. 
 
2.2.3 Fitting the treatment effect model by SMBG data 
In this study, self-monitored blood glucose(SMBG) data from real clinical treatment are 
used to estimate the parameters in the model. Let {𝑙1, 𝑙2, … , 𝑙𝑇} denote the blood glucose 
level recorded from day 1 to day 𝑇, then parameter 𝜷 for that phase is obtained by solving 
the non-negative least square (NNLS) problem 
             𝜷∗ = argmin
𝛽≥0
 𝐸𝑟𝑟(𝜷) = argmin
𝛽≥0
∑ (𝑙𝑡 − 𝐵𝐺𝐿(𝜷, 𝑡))
2𝑇




An efficient gradient descent algorithm is developed to solve (2.2.17). To ensure non-
negativity of 𝜷 throughout the gradient descent algorithm, we first replace 𝜷 with ?̂? =
(𝑙𝑛(𝐵𝑎𝑠𝑒), 𝑙𝑛(𝛼), 𝑙𝑛(𝐸𝑚𝑎𝑥), 𝑙𝑛(𝑅𝑑), 𝑙𝑛(𝑘𝑒𝑞)).  





2 as the treatment effect at time t with 
dose 𝐷t. By (2.2.13), we have 
                𝐵𝐺𝐿(?̂?, 𝑡 + 1) =  𝐵𝐺𝐿(?̂?, 0) + ∑ T(?̂?, 𝐷𝑠, 𝑠)
𝑡
𝑠=0  






𝑠=0         (2.2.18) 
And the gradient is calculated as  











𝑠=0      (2.2.19) 
Therefore, 𝐵𝐺𝐿(?̂?, 𝑡)  and its gradient 
𝜕𝐵𝐺𝐿(?̂?,𝑡)
𝜕?̂?
 can be obtained simultaneously as we 
calculate the objective value 𝐸𝑟𝑟(?̂?), which is efficient in terms of computational cost.  
 
2.3 Result and Discussion 
We tested the treatment effect model on 14 de-identified patients with GDM. Eight of them 
are African American, and six are Caucasian American. Furthermore, three patients have 
history of GDM; three have a history of DM; 4 patients are obese; one patient has 




2.3.1 Establishing the predictive treatment effect parameters 
In this study, SMBG data from real clinical treatment are used to fit the treatment effect 
model. Each patient was asked to record her blood glucose level at 4 different times/phases 
of a day: before breakfast(BB), after breakfast(AB), after lunch(AL) and after dinner(AD) 
until delivery. Since the activity and food intake are different between different phases, 
each phase will have its own treatment effect model fitted by the SMBG data recorded at 
that phase. For example, a patient may have a good glycemic control before breakfast but 
a poor control after breakfast because she is not compliant to diet control. Therefore, each 
patient will have 4 sets of parameters of the treatment effect model estimated to 
characterize her personalized disease progression and dose response.  
Missing data are common in SMBG as patients often forget or fail to measure it. Although 
a SMBG reading may be missing on day 𝑡, the prescription dose 𝐷t is known and both 
𝐵𝐺𝐿(𝜷, 𝑡)  and the gradient will be calculated. However, they are only used in the 
calculation of future 𝐵𝐺𝐿 and are excluded in the calculation of the total squared error 
𝐸𝑟𝑟(𝜷).  
Since the problem min
𝛽≥0
 𝐸𝑟𝑟(𝜷)  is nonconvex in the corresponding parameters 𝜷 , the 
gradient descent algorithm cannot guarantee global optimality of the solution. As a result, 
different choices of the initial value of 𝜷 can lead to different estimations. To avoid local 
optima and ensure the quality of the solution, we run the algorithm 10 times with different 
initial values and choose the one with the minimum estimation error. Different initial 
values are chosen according to the population mean and variance of these parameters in 




differ very much to the population mean. For these patients with gestational diabetes, 
according to our experiment, the initial value for 𝐵𝑎𝑠𝑒 could be 90 ± 10 mg∙dl-1 for the 
phase of before breakfast and 130 ± 10 mg∙dl-1 for other phases. 𝛼  could be 0.005 ±
0.001 mg∙dl-1∙day-1, 𝐸𝑚𝑎𝑥 could be 90 ± 10 mg∙dl
-1, 𝑅𝑑 could be 0.2 ± 0.1 mg
-1 and 𝑘𝑒𝑞 
could be 0.05 ± 0.01 day-1. However, in real practice, other values can be used to shows 
the importance of each parameter in the model and reflects clinician’s initial judgement of 
the patient’s dose response. 
 
2.3.2 Model validation and comparison  
The moving average(MA) is often used to uncover the trend of the time series data. 
Therefore, we will compare the moving average of blood glucose level to the predicted 
level to evaluate the performance of our model. For time series {𝑋𝑡} the moving average 
of window size 𝑞 is defined by 
     𝑊𝑡 = (2𝑞 − 1)
−1 ∑ 𝑋𝑡−𝑗
𝑞
𝑗=−𝑞    (2.3.1) 
Based on the SMBG data, we calculated the moving average of the blood glucose level 
with window size 7 (fig. 2.3 left). By checking the residual of the glucose data, we can 
assume that the data series, after subtracting the moving average, is approximately 
stationary (fig. 2.3 right). The outliers are chosen if they are three times standard deviation 






Figure 2.3. Left: Blood glucose level recorded before breakfast of patient 1. Right: Q-Q plot of the 
residual of blood glucose data after the moving average is subtracted 
 
We also developed an autoregression model(AR) to compare with our treatment effect 
model. Autoregression models are commonly used to describe certain time-varying 
process. The model specifies that the signal is linearly dependent on its previous values 
and a stochastic noise. In this study, an AR model describing the SMBG data is developed 
as follows: 
𝐵𝐺𝐿(𝑡) = 𝑐 + θ1 ∙ 𝐵𝐺𝐿(𝑡 − 1) + θ2 ∙ 𝐵𝐺𝐿(𝑡 − 2)  +  𝛾 ∙ 𝐷t + δ ∙ 𝑡 + ε𝑡,   t = 1 … T − 1 (2.3.2) 
This is an AR model with lag 2 and constant 𝑐, exogenous predictor variables 𝐷t and linear 
trend value δ. ε𝑡 is the random Gaussian noise. We used AR(2) model simply because it 
gives better fitting than AR(1) model based on our experiment. The biggest difference 
between (2.2.13) and (2.3.2) is the term that characterizes the treatment effect. In (2.2.13), 
the treatment effect is modeled as the mixed effect of disease progression and drug effect, 









drug dosage 𝐷t and treatment time 𝑡. Therefore, we want to explore the benefit of using 
mechanism-based PK/PD model against the descriptive model totally based on the 
observed data.  
For both methods, the dosage level 𝐷t comes from the dose regimen that clinicians used 
for the patient in real treatment. The patients and her doctor meet every week to monitor 
the disease progression. Drug dosage will possibly be changed after checking the outcome 
of previous regimen. For each patient, the first 4 weeks of SMBG data (or first 50% for 
small datasets), which we refer to as the titration period, are used to fit both models. Once 
the parameters are estimated, the remaining data is used to validate the predicted blood 
glucose level of the model. The blood glucose values after the 4th week is predicted by the 
fitted model using the original dose regimen applied for the patient. For the AR(2) model, 
the value is predicted by 
𝐵𝐺𝐿(𝑡) = ?̂? + θ̂1 ∙ 𝐵𝐺𝐿(𝑡 − 1) + θ̂2 ∙ 𝐵𝐺𝐿(𝑡 − 2) + γ̂ ∙ 𝐷t + δ̂ ∙ 𝑡 ,   t = 1 … T − 1   (2.3.3) 
where ?̂?, θ̂1, θ̂2, γ̂, δ̂ are the maximum likelihood estimators. For the treatment effect model, 
the value is predicted by 





2   (2.3.4) 
and 𝐵𝐺𝐿(0) = 𝐵𝑎𝑠?̂? . The parameter ?̂?, ?̂?𝑚𝑎𝑥 , ?̂?𝑑 , ?̂?𝑒𝑞  and 𝐵𝑎𝑠?̂?  are then obtained by 





Figure 2.4. Result of fitting the treatment effect model for patient 1 in all 4 phases: before 
breakfast(BB), after breakfast(AB), after lunch(AL), after dinner(AD). The moving average(red 
dotted line) is calculated using all SMBG data with window size 7. The predicted level(green curve) 
is obtained by using the treatment effect model fitted by the first 4 weeks SMBG data(purple cross) 
and the dose regimen(black dash dotted line). 
 
The result of fitting the treatment effect model for patient 1 is shown in fig. 2.4. Several 
dose escalations occur during the early stage of the treatment (titration period) and the 
maintenance dose of 8.75mg is kept for most of the time during the rest of treatment. 
Therefore, the trend of blood glucose level, under such dose regimen, is gradually 
decreasing over time. The treatment effect model captures the disease progression and dose 
response information of the patient from the titration period and gives good prediction on 




same training data, gives less accurate prediction on the trend of blood glucose level (fig. 
2.5). For all 4 phases, the predicted blood glucose level is higher than the moving average. 
The prediction accuracy of the two methods is measured and compared by the root-mean-
square error (RMSE) defined as  





)    (2.3.5) 
Across all 14 patients, the RMSE of the treatment effect model is less than the AR(2) 




100% , is -8.77% with 95% CI = [−16.73, −0.81]  for before breakfast, -7.23% with 
95% CI = [−19.69, 5.23]  for after breakfast, -9.87% with 95% CI = [−18.14, −1.60] 
for after lunch and -9.49% with 95% CI = [−21.54, 2.55] for after dinner. The result 
shows that our treatment effect model performs better at predicting the long-term blood 
glucose level than the AR(2) model. SMBG data often has high variability due to 
personalized food intake and poor compliance. Additionally, missing data is common as 
patients often forget to record it. Therefore, the AR model, like other descriptive methods, 
gives worse estimation and prediction for such dataset. However, our treatment effect 
model shows that it is robust to high variability and large amount of missing data. It models 






Figure 2.5. Result of fitting the AR(2) model for patient 1 in all 4 phases: before breakfast(BB), 
after breakfast(AB), after lunch(AL), after dinner(AD). The first 4 weeks data(purple line) are used 
for fitting the model and the first week data serve as the initial value for predicting future values. 
The predicted level of AR(2) model(orange curve) is compared to the moving average(red dotted 
line) and the predicted level of the treatment effect model(green curve). 
 
2.4 Conclusion 
In this chapter, we developed a treatment effect model that combines disease progression 
with a PK/PD drug effect model. This mechanism-based PK/PD model establishes the 
direct relationship between drug dosage and drug effect (the amount of decrease in blood 
glucose level), which overcomes the obstacle of many existing models that require 
continuous measurement of insulin or drug concentration in the blood. It utilizes the most 
commonly collected SMBG data in diabetes management to estimate the dose response of 




tells the personalized characteristics of each patients, including dose response, disease 
progression and compliance. Moreover, compared to descriptive models, the model gives 
better long-term prediction on the trend of blood glucose level. Such information can help 
clinicians get a better understanding of each patient and target treatment to the patient’s 
specific needs. Also, it is the first model that tries to build the direct relationship between 
drug dosage and blood glucose level. Therefore, doctors can quantitatively optimize the 
dosing strategy based on patient’s personalized disease progression and dos response so 
that better treatment outcome can be achieved. Currently, the treatment of GDM and other 
types of diabetes rely heavily on clinicians’ experience. However, it is unrealistic to expect 
the human mind to be able to address the complexity, variability, and uncertainties of health 
and disease. Therefore, this treatment effect model, which only uses SMBG, provides 
clinicians a good insight on a patient’s personalized dose response and potentially guides 
their decision making during the treatment.  
With more patients studied, we can use machine learning techniques to identify specific 
characteristics of patients that relate to the dose response and disease progression pattern. 
Therefore, patient’s dose response can be predicted at the beginning of the treatment so 









DOSE-EFFECT EVIDENCE-BASED PERSONALIZED 
TREATMENT PLANNING FOR MANAGING GESTATIONAL 
DIABETES MELLITUS 
The content of this chapter is based on two manuscripts:  
[9]Eva K. Lee, X.W., Francine Baker-Witt, Michael D. Wright, Alexander Quarshie, 
Outcome-Driven Personalized Treatment Design for Managing Diabetes. Interfaces - The 
Daniel H. Wagner Prize for Excellence in Operations Research Practice. To appear 2018 
[11]Eva K. Lee, X.W., Francine Baker-Witt, Michael D. Wright, Alexander Quarshie, 
Dose-effect Evidence-based Personalized Treatment Planning for Managing Gestational 
Diabetes Mellitus. 2018: Diabetes Care. Manuscript submitted for publication. 
 
3.1 Introduction 
Gestational diabetes mellitus (GDM) is defined as any degree of glucose intolerance with 
onset or first recognition during pregnancy[40]. Women with GDM and elevated glucose 
levels are at higher risks of maternal and fetal complications during pregnancy and birth, 
including shoulder dystocia, birth injuries, hypoglycemia, respiratory distress syndrome, 
cesarean section, pre-eclampsia and fetal overgrowth[41]. It can also trigger the occurrence 




pregnancies, resulting in over 200,000 cases annually[43], and incurs approximately $636 
million of annual treatment cost[44]. 
Though the precise mechanisms underlying gestational diabetes remain unknown, the 
diagnosis of GDM presumes a threshold value above which women are at increased risk of 
pregnancy complications[45]. It is shown that the risk for both short-term and long-term 
complications can be mitigated by glycemic control during pregnancy[46]. As a result, the 
management of GDM targets close monitoring of blood glucose levels up to 4 times a day: 
before breakfast (fasting level) with goal ≤ 95 mg/dl and two hours after each meal with  
goal ≤ 120mg/dl[47]. The treatment of GDM is similar to Type 2 diabetes. Dietary control 
and physical activities are the most common interventions. If they fail to control the blood 
glucose level, more effective insulin therapies will be prescribed[48]. Oral hypoglycemic 
agents (OHAs), though not approved by FDA for treating pregnant women, are also 
common GDM drugs because of easy usage and low cost. Glibenclamide/Glyburide, which 
is used in this study, has been proven an effective alternative to insulin for achieving 
adequate glycemic control[49]. In real practice, combination therapies are often prescribed 
to achieve better treatment outcome.  
Many clinical trials have been performed to evaluate the efficacy of different types of 
therapies for GDM[50-56]. Scarpello reviewed the United Kingdom Prospective Diabetes 
Study and identified an optimal dosing strategy for treating diabetes with metformin[57]. 
The author showed that the anti-hyperglycemic efficacy of metformin increases with 
increasing daily doses between 500 mg and the upper limits of the recommended daily 
dosage (≥ 2000 mg/day). Alwan et al. systematically reviewed eight different randomized 




Comparing specific treatment (e.g. dietary advice, glucose monitoring, and insulin therapy) 
with routine antenatal care, there was a reduction in the proportion of infants weighing 
more than 4 kilograms or greater than 90th birth percentile. While GDM treatment appears 
to be useful, there is no evidence indicating which treatment is best or how long-term 
treatment outcomes can be assessed[58]. 
One of the key problems in diabetes management is to choose the right drug with right dose 
to treat the right patient. However, it becomes increasingly complex now because of the 
variability in patients and the widening alternatives of pharmacological agents. Clinicians 
make their decisions based on personal experience and clinical guidelines. These evidence-
based advice, which mainly comes from clinical trials, does not address the different 
choices of drugs and only shows the median responses of the recruited patients. In this 
chapter, we address the dosing strategy in GDM management by introducing a patient-
centered decision support tool that couples a treatment-effect model with a dose 
optimization mode. The treatment-effect model, which is introduced in the chapter II, is a 
mechanism-based PK/PD model that captures the underlying glucose dynamics and 
personalized drug effects of each patient. Self-monitoring of blood glucose (SMBG) is 
commonly used as a tool of self-management in diabetes treatment. However, the 
effectiveness of SMBG on glycemic control is still not clear[59]. Our model provides a 
new mathematic tool to utilize SMBG data in diabetes management. These data, which are 
recorded by patients at home, are used to estimate the personalized disease progression and 
dose response characteristics of patients. And a mixed-integer program is developed to 




horizon. To the best of our knowledge, this is the first model that quantitatively optimizes 
dosing strategy through mathematical programming. 
  
3.2 Method 
3.2.1 The treatment effect model 
To optimize the dosing strategy, we need to first estimate the effect of drugs on the blood 
glucose level. In chapter II, we developed a mechanism-based treatment effect model that 
build the direct relationship between the drug dosage to the blood glucose level. In that 
model, the blood glucose level changes by a combination effect of linear disease 
progression and drug effect from anti-diabetic drugs. 
𝐵𝐺𝐿(𝑡) = 𝐵𝑎𝑠𝑒 +  𝛼 ∙ 𝑡 − 𝐸𝑚𝑎𝑥 ∙
𝐷 ∙ 𝑅𝑑 ∙ (1 − 𝑒
−𝑘𝑒𝑞∙𝑡)
1 + 𝐷 ∙ 𝑅𝑑 ∙ (1 − 𝑒
−𝑘𝑒𝑞∙𝑡)
 
where 𝐵𝑎𝑠𝑒 is the baseline blood glucose level at the beginning of the treatment. 𝛼 is the 
constant rate of disease progression. As diabetes is a progressive disease, the blood glucose 
level is expected to increase due to the deterioration of the ability to control glucose by 





 models the expected 
reduction of blood glucose level by taking drug with dosage 𝐷. 
In chapter II we showed that the treatment effect model can give good estimate and forecast 
of the trend of blood glucose level during the treatment. The model has four distinct 




uncovers the effect of different drug dosages on the value of blood glucose level. Though 
PK/PD models are widely used in all phases of preclinical and clinical drug development, 
little research has been done to apply those concepts in clinical therapy. Second, self-
monitored blood glucose (SMBG) data are utilized to fit the model and estimate the 
personalized dose response and disease progression. This data is readily available as 
SMBG is widely used in diabetes management. Therefore, unlike other models which 
requires continuous monitoring of drug concentration in body fluids, our model is easily 
implementable in current clinical setting. Third, this mechanism-based PK/PD model, 
fitted by the blood glucose level recorded during the titration period (dosing experiment 
period), has the ability to predict the blood glucose level in the future. Compared to the 
descriptive autoregression models, our model is robust to the high variability and large 
number of missing values in SMBG data and gives better long-term prediction on the trend 
of blood glucose level. Last and most importantly, the model is fitted for each patient 
separately to get the personalized characteristics of dose response and disease progression.  
 
3.2.2 Dose Optimization Model 
The management of GDM starts with the diagnosis of the gestational diabetes (usually at 
weeks 24-28) and ends after the delivery. There are 3 types of treatment for gestational 
diabetes: (1) diet control only, (2) oral hypoglycemic agents (OHAs) therapy with diet 
control, and (3) insulin therapy with diet control. In this dissertation, we only consider the 
first two methods since insulin therapy is not used for our patients. The initial plan is 
decided when diagnosis is made and is set by determining the treatment type and the dosage 




subsequent clinical visits until delivery. Patients are asked to record their blood glucose 
level at different times/phases of a day. The decisions are made after assessing the impact 
of prior treatment according to the self-monitored blood glucose (SMBG) data (fig. 3.1). 
Therefore, the dosing strategy is to decide on the weekly dosage level of the drug. 
 
 
Figure 3.1. Decision process for the treatment of pregnant women with gestational diabetes 
 
Currently the dosing strategy of GDM relies heavily on the result of clinical trials and 
clinician’s personal experience. However, clinical trials often address the (trial) patient 
population for whom the intervention is appropriate, instead of individual patient 
characteristics. A trial-and-error approach is often used for clinicians to overcome the 
complexities and variabilities in each patient. In this paper, we developed a mixed-integer 
program that incorporates the treatment effect model to individualize and optimize the 
dosing strategy for treating GDM patients. Each patient’s personalized disease progression 
and dose response are estimated from the daily SMBG data. The treatment effect model, 
as shown in chapter II, can give long-term prediction on how the trend of blood glucose 
level goes given different drugs and dosages. Therefore, we can quantitatively optimize the 




estimations and predictions are based on patient’s individual evidence, the optimized dose 
regimen tailors to the patient specific characteristics so that the treatment outcome is better 
than a trial-and-error approach.  
In Table 3.1 below, we introduce the parameters and decision variables used in our model.   
Indices  
𝒘 index for week, 𝑤 = 1, … , 𝑊 
𝒎 index for phase of daily blood glucose level, 𝑚 = 1, … ,4 
𝒕 index for days during a week, 𝑡 = 1, … ,7 
𝒊 drug dosage level, 𝑖 = 0, … , 𝐿 
Parameters  
𝒈(𝒎, 𝒘, 𝒕, 𝒊) Treatment effect for dosage level 𝑖 at week 𝑤 day 𝑡 and phase 𝑚. 
𝑪+ Cost of positive deviation of blood glucose level from upper bound level 
𝑪− Cost of negative deviation of blood glucose level from lower bound level 
𝑪(𝒊) cost of drug at dosage level 𝑖 
𝑾 total number of weeks 
𝑳 total number of dosage levels (dosage level increase 1.25mg per level). 
𝒌+ maximum positive dosage level change between 2 consecutive decisions 
𝒌− maximum negative dosage level change between 2 consecutive decisions 
𝑻(𝒎) upper bound of blood glucose level for phase 𝑚 
𝑩(𝒎) lower bound of blood glucose level for phase 𝑚 
Decision variables  
𝒙(𝒘, 𝒊) 
binary decision variable equals 1 if dosage level 𝑖 is applied for week 𝑤, 0 
otherwise. 
𝒔(𝒎, 𝒘, 𝒕) blood glucose level at week 𝑤 day 𝑡 phase 𝑚 
𝒑(𝒎, 𝒘, 𝒕) positive deviation of blood glucose level at week 𝑤 day 𝑡 phase 𝑚 
𝒏(𝒎, 𝒘, 𝒕) negative deviation of blood glucose level at week 𝑤 day 𝑡 phase 𝑚 
 
The treatment planning model can be formulated as                          
    (𝐌𝐈𝐏)  𝑀𝑖𝑛     ∑ ∑ ∑ 𝑓1(𝑚, 𝑤, 𝑡)𝑡𝑤𝑚 + ∑ ∑ 𝑓2(𝑤, 𝑖)𝑖  𝑤  
     𝑠. 𝑡.    𝑓1(𝑚, 𝑤, 𝑡) = 𝐶+ ∙ 𝑝(𝑚, 𝑤, 𝑡) + 𝐶− ∙ 𝑛(𝑚, 𝑤, 𝑡),      ∀ 𝑚 = 1 … 4, 𝑤 =
1 … 𝑊, 𝑡 = 1 … 7  (3.2.1)                                                                    




              ∑ 𝑥(𝑤, 𝑖) = 1,       ∀ 𝑤 = 1 … 𝑊 𝑖  (3.2.3) 
         𝑠(𝑚, 𝑤, 𝑡) = 𝑠(𝑚, 𝑤, 𝑡 − 1) + ∑ 𝑔(𝑚𝑖 , 𝑤, 𝑡 − 1, 𝑖) ∙ 𝑥(𝑤, 𝑖), ∀ 𝑚 = 1 … 4, 𝑤 =
1 … 𝑊, 𝑡 = 1 … 7  (3.2.4) 
              𝑠(𝑚, 0,0) = 𝑏𝑎𝑠𝑒(𝑚), ∀ 𝑚 = 1 … 4   (3.2.5) 
             𝑝(𝑚, 𝑤, 𝑡) ≥ 𝑠(𝑚, 𝑤, 𝑡) − 𝑇(𝑚),      ∀ 𝑚 = 1 … 4, 𝑤 = 0 … 𝑊, 𝑡 = 1 … 7  (3.2.6) 
             𝑛(𝑚, 𝑤, 𝑡) ≥ 𝐵(𝑚) − 𝑠(𝑚, 𝑤, 𝑡),      ∀ 𝑚 = 1 … 4, 𝑤 = 0 … 𝑊, 𝑡 = 1 … 7  (3.2.7) 
𝑥(𝑤 − 1, 𝑖) + ∑ 𝑥(𝑤, 𝑗) + ∑ 𝑥(𝑤, 𝑗) ≤ 1
𝑗>𝑖+𝑘+𝑗<𝑖−𝑘−
, ∀ 𝑤 = 1, … 𝑊, 𝑖 = 0, … , 𝐿  (3.2.8) 
                         𝑠 ≥ 0, 𝑝 ≥ 0, 𝑛 ≥ 0, 𝑥 ∈ 𝐵𝑊×𝐿 ,  𝑥(0,0) = 1  (3.2.9)  
There are two objectives in this mixed-integer program. The first objective (3.2.1) is to 
minimize the total positive and negative deviation of the blood glucose level to the 
recommended target level. The positive deviation is calculated by (3.2.6) where the upper 
bound is 120mg/dl to ensure satisfactory glycemic control. The negative deviation is 
calculated by (3.2.7) where the lower bound is set to be 60mg/dl to avoid hypoglycemia. 
Basically, we want to control the expected blood glucose level within 60mg/dl ~ 120mg/dl. 
The second objective (3.2.2) is to minimize the total drug dosage. Although OHAs are 
commonly used for treating GDM, they are not formally approved.  Minimizing dosage 
thus serves to improve safety for these patients. Constraint (3.2.3) ensures that a dosage 
level is selected for each week. Since OHAs are mostly in the form of pills, drug dosage in 
our model is restricted to discrete level. Dosage level 0 implies that the patient is on diet 




the change of blood glucose level as a result of the drug dosage, as modelled in chapter II. 
Here we use the (2.2.13), which is 





2      (3.2.10) 
Therefore, 





  (3.2.11) 
where 𝐷𝑖 is the 𝑖-th dosage level. The parameters (𝐵𝑎𝑠𝑒, 𝛼, 𝐸𝑚𝑎𝑥 , 𝑅𝑑, 𝑘𝑒𝑞) are estimated 
from patient’s daily SMBG readings of phase 𝑚. As a result, the optimized dose regimen 
will be personalized. Constraint (3.2.8) follows clinical practice that the dosage level 
should not fluctuate too much from one visit to the next. Since there is no national standard 
regarding the choice, the fluctuation allowed can be physician dependent. In practice, 
clinicians always start with diet control only at the start of the visit. We comply with this 
practice by setting the initial treatment at week 0 with no dosage, which is 𝑥(0,0) = 1. 
 
3.3 Result and discussion 
A retrospective analysis of 14 de-identified patients is performed in this study.  Table 3.2 
shows the statistics of these patients. Eight of them are African American, and six are 
Caucasian American. Furthermore, three patients have history of GDM; three have a 




Table 3.2. Patient statistics by age, height, weight, BMI and length of GDM treatment 
 Age Height(inch) Weight(lb) BMI(kg∙m-2) Length(day) 
Min 20 59 122 22.7 26 
Max 41 70 260 50.8 153 
Mean 33.7 62.9 184.5 32.8 79.5 
Median 34.5 62 181.5 33.2 68.5 
Standard 
deviation 
5.3 3.0 38.6 6.5 38.8 
 
For each patient, the blood glucose level is recorded at 4 different phases of a day: before 
breakfast(BB), after breakfast(AB), after lunch(AL) and after dinner(AD).  Therefore, each 
patient will have 4 sets of parameters of the treatment effect model estimated to 
characterize her personalized disease progression and dose response.  
The parameters of the treatment effect model are obtained by a fast gradient descent 
algorithm described in chapter II. They are then put into (3.2.4) and (3.2.5) to formulate 
the optimization model. The treatment horizon is set to be the same as the real treatment. 
All patients are treated by Glyburide and the dosage level is discretized as 1.25mg per level, 
which is the minimum weight of a Glyburide tablet sold in drug store. The upper bound 
target blood glucose levels are 95mg/dl before breakfast and 120mg/dl after meals. A lower 
bound baseline blood glucose levels of 60mg/dl for all 4 phases are also included to avoid 
hyperglycemia.  
The optimization problem is solved by CPLEX® 12.6. Even though the model is a mixed-
integer program, it has a simple constraint sets and can be solved efficiently. The average 
solution time of 14 patients is 3.27 secs. In fig. 3.2 left, we contrast the optimized regimen 




glucose level than the original one. In terms of total positive deviation, which is calculated 
as ∑ (𝐵𝐺𝐿(𝑡) − 𝑇)+𝑡 , where 𝑥+ = max (𝑥, 0)  and 𝑇  is the upper bound blood glucose 
level, the optimized dosing strategy results in lower (or the same) value for all 4 phases 
compared to the original treatment regimen (fig. 3.2 right). 
Table 3.3 summarizes the optimized dose regimen produced by our model and the 
comparison to the original dose regimen used in real treatment. In this retrospective study, 
we observe that the optimized dose regimen from our model tends to prescribe a higher 
dose early on, and there is no change on dosage after Week 3. Therefore, the titration period 
is significantly shortened, and the maintenance dosage level will be quickly achieved. This 
demonstrates that, with accurate estimation of patient’s dose response characteristics, the 
model allows clinicians to prescribe higher dose at the early stage with confidence without 
the concerns of overdosing. This is in agreement with recommendations to quickly increase 
the dose of oral hypoglycemic agent until adequate glycemic control is achieved or 
response is not observed[36].  
 
Figure 3.2. Comparison of original regimen vs. optimized regimen of patient 5. Left: the predicted 
trend of blood glucose level under the treatment effect model using original and optimized regimen. 





Among these 14 cases, 4 of the optimized plans are identical to the original plans (Patients 
4, 7, 12, 13). Of the remaining 9, all experience reduction in blood glucose (fig. 3.3) and 4 
of the optimal plans use fewer drugs, too. We could not draw any conclusion for Patient 6 
because of large number of missing data. From the result, we can see that the optimized 
dose regimen can provide better glycemic control and use fewer drugs at the same time. 
This proves that the dose optimization model, incorporated by the predictive treatment 
effect model can potentially can produce a personalized, drug efficient dose regimen that 
maximizes the treatment outcome for GDM patients. 
Table 3.3. This table compares the dosage level of the optimized regimen (Opt) versus the 
original clinical regimen (Real) in a 10-week treatment horizon. Dosage prescribed for each 
week are shown and followed by the difference of total positive deviation of glucose level 
between optimized plan and the original plan. A negative value indicates that the optimized 
plan is better in glycemic control than the clinical plan. All 4 phases are reported. 
 Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
week Real1 Opt2 Real Opt Real Opt Real Opt Real Opt 
1 0 0 0 0 0 0 0 0 0 0 
2 1.25 5 2.5 5 5 5 5 5 2.5 5 
3 5 5 3.75 10 10 6.25 5 5 2.5 10 
4 8.75 5 3.75 15 10 6.25 5 5 5 15 
5 8.75 5 5 15 10 6.25 5 5 5 15 
6 8.75 5 5 15 10 6.25 5 5 10 15 
7 10 5 5 15 10 6.25 5 5 15 15 
8 8.75 5 6.25 15 15 6.25 5 5 15 15 
9   8.75 15   5 5 15 15 
10   8.75 15   5 5 15 15 
Total 51.25 35 48.75 120 70 42.5 45 45 85 120 
Reduction of total positive deviation over the entire treatment horizon (Opt – Real, mg/dl)3 
BB - 0.00 - -48.86 - -1.99 - 0.00 - -307.15 
AB - -36.73 - 0.00 - -26.73 - 0.00 - -27.19 
AL - -42.25 - 0.00 - -23.61 - 0.00 - -63.83 







Table 3.3 continued 
 Patient 6 Patient 7 Patient 8 Patient 9 Patient 10 
week Real Opt Real Opt Real Opt Real Opt Real Opt 
1 2.5 0 0 0 0 0 2.5 0 0 0 
2 5 5 0 0 5 5 2.5 0 0 1.25 
3 5 6.25 0 0 5 6.25 2.5 0 0 1.25 
4 7.5 6.25 0 0 5 6.25 2.5 0 5 1.25 
5   0 0 5 6.25 2.5 0 5 1.25 
6   0 0   2.5 0 5 1.25 
7   0 0   2.5 0 5 1.25 
8   0 0   2.5 0 5 1.25 
9   0 0   2.5 0 5 1.25 
10   0 0   2.5 0 5 1.25 
Total 20 17.5 0 0 20 23.75 25 0 35 11.25 
Reduction of total positive deviation over the entire treatment horizon (Opt – Real, mg/dl)3 
BB - N/A - 0.00 - 0.00 - 0.00 - -9.52 
AB - N/A - 0.00 - -0.08 - 0.00 - 0.00 
AL - N/A - 0.00 - 0.00 - 0.00 - 0.00 
AD - N/A - 0.00 - -0.03 - 0.00 - 0.00 
Table 3.3 continued 
 Patient 11 Patient 12 Patient 13 Patient 14 
week Real Opt Real Opt Real Opt Real Opt 
1 0 0 0 0 0 0 0 0 
2 2.5 5 0 0 0 0 0 5 
3 2.5 8.75 0 0 0 0 5 5 
4 2.5 8.75 0 0 0 0 2.5 5 
5 5 8.75 0 0 0 0 5 5 
6 5 8.75 0 0 0 0 5 5 
7 5 8.75 0 0 0 0 5 5 
8 5 8.75 0 0 0 0 5 5 
9 5 8.75 0 0 0 0 5 5 
10 7.5 8.75 0 0   5 5 
Total 40 75 0 0 0 0 37.5 45 
Reduction of total positive deviation over the entire treatment horizon (Opt – Real, mg/dl)3 
BB - -527.03 - 0.00 - 0.00 - 0.00 
AB - -36.10 - 0.00 - 0.00 - -36.73 
AL - 0.00 - 0.00 - 0.00 - -42.25 
AD - -361.27 - 0.00 - 0.00 - -23.70 
1. Original clinical regimen used in the real treatment 
2. Optimal regimen produced by our optimization model 
3. Total positive deviation of optimal regimen– total positive deviation of original regimen (over 






Figure 3.3. Box-Whisker plot of the reduction of total positive deviation over the entire treatment 
horizon of each phase 
 
There are two objectives in the optimization: health outcome, which is the total positive 
and negative deviation of blood glucose level, and drug dosage cost. We optimize them by 
using the weighted sum of two objectives. The cost of drug increases with the dosage 
level. 𝐶(𝑖) = 𝑖, 𝑖 = 0, … ,16 where 𝑖 corresponds to dosage level 1.25 ∗ 𝑖 mg. Define α =
𝐶+/𝐶(1) as the ratio of the cost of total positive deviation to the cost of drug dosage. The 
blood glucose level from optimized dose regimen never goes below the lower bound. So 
we do not consider 𝐶− here. The different choices of ratio α reflect the importance of each 
objectives. With the increase of α , the optimized dosing strategy will change from 
minimizing drug dosage to improving health outcome (fig. 3.4 left). Since high blood 
glucose level relates to complications in delivery, glycemic control is more important than 
drug cost in managing GDM. From the experiment on all patient cases, there is no 
significant changes on the value of total positive deviation when α is greater than 0.3(fig. 
3.4 right). Therefore, we select α = 0.3 in the optimization to place more emphasis on the 





Figure 3.4. Left: The efficient frontier of the two-objective optimization. The numbers are the 
different cost ratio 𝛼 . Right: The change of total drug dosage and total positive deviation for 
optimized plan as the cost ratio 𝛼 increases. 
 
3.4 Conclusion 
In this chapter, we developed a dose optimization model for treating gestational diabetes. 
The model incorporates patient’s personalized dose response characteristics to 
individualize and optimize the weekly dose prescription in a given treatment horizon. Such 
personalized evidence is estimated by a treatment effect model developed from classic 
PK/PD theory. This mechanism-based model provides a new mathematical way to analyze 
the daily SMBG data recorded by patients at home and extract insights of patient’s unique 
disease progression and dose response information. Moreover, it provides an opportunity 
to quantitatively optimize the dosage level to manage the disease effectively. In a 
retrospective study, we tested the model on 14 clinical patients with GDM. The optimized 
regimens from our model, compared to the original regimens, produce better glycemic 
control with even smaller amount of drug prescribed. Moreover, this mixed-integer dose 
optimization model is solved fast and can be potentially used in real-time setting such as 




the complexity and variability in diabetes management and improve their decision making 
on dose prescription. In the future, more practical constraints can be identified by doctors 
and added to the optimization model to improve the result.  
This work forms the foundation of a larger study of treatment of general diabetes patients. 
We have performed a larger study that involves hundreds of patients (GDM patients, and 
other types of diabetic patients) to further explore and validate our model [8]. We caution 
















MULTI-OBJECTIVE DIRECT APERTURE OPTIMIZATION 
MODEL FOR RADIOTHERAPY PLANNING 
 
The content of this chapter Section 4.2 and 4.3 is based on three submitted manuscripts: 
[12]Eva K. Lee, X. Wei, Z. Li, Isocenter Selection in Radiation Therapy Treatment 
Planning. 2018: Medical Physics. Manuscript submitted for publication.  
[13]Eva K. Lee, X. Wei, Z. Li, A Multi-Objective Direct Aperture and Beam Angle 
Optimization Model for External Beam Radiotherapy. 2018: International Journal of 
Radiation Oncology • Biology • Physics. Manuscript submitted for publication. 
[14]Eva K. Lee, Y. Cao, X. Wei, Z. Li, Strategies in Aperture Generation within a Multi-
Objective Direct Aperture and Beam Angle Optimization Framework. 2018: International 




Cancer is a major cause of morbidity and mortality with approximately 14 million new 
cases and 8 million cancer-related deaths worldwide in 2012[60]; and more than half of the 
patients receive radiotherapy during the course of treatment. Radiotherapies use ionizing 
radiation to damage the DNA of cells and exploit the fact that the recovery ability of 




is to deliver sufficient dose to the tumor cells while sparing the surrounding normal tissues 
and critical organs. In external radiotherapy, this is achieved by using linear accelerator 
(LINAC) to generate multiple beams from different angles to crossfire the tumor so that 
tumor cells can be killed at a sufficiently high probability to control malignant disease and 
normal cells are kept safe by receiving a relatively low dose (fig. 4.1). Such technique is 
also known as three-dimensional conformal radiation therapy (3-DCRT). Field-shaping 
devices (e.g. wedges, blocks) are used to make the dose volume conform to the target 
shape. Beam parameters including beam geometries, beam weights will be set in a trial-
and-error way to generate the best possible plan[61].  
Intensity modulated radiation therapy, which is often called IMRT, improves the 3-DCRT 
by modifying the beam intensities across a radiation field using multi-leaf collimators 
(MLC). This increased freedom provides the ability to better shape the high dose volume 
to the tumor while avoiding the normal tissues. The optimization of IMRT plans starts with 
the desired dose requirement for tumor and normal organs and works backward to optimize 
the beam intensities. This is often referred to as inverse treatment planning[62]. In 2008, 
Otto introduced volumetric modulated arc therapy (VMAT) technique that allows machine 
dose-rate variation and can deliver the plan in a single arc of up to 360 degree[63]. The 
CyberKnifeTM system (Accuray Incorporated, Sunnyvale, CA, USA) uses a LINAC 
mounted on a robotic arm to deliver radiation with non-isocentric and non-coplanar beams 
with high precision. A tracking system is also implemented to monitor the respiration 
motion of patients during treatment and adjust the delivery configuration accordingly[64]. 




which uses many beams with low intensity to target one or more tumors, is very effective 
in killing tiny tumors in brain and has little side effect on normal brain tissues. 
 In general, the treatment planning process of radiation therapy consists of the following 
steps: 
• 3D Imaging of tumor sites and the surrounding region 
• Delineating tumor and other anatomical structures 
• Determining the required dose to tumor and tolerance dose to normal structures 
• Selecting a set of beam orientations and target points 
• Calculating dose for each beam 
• Optimizing beam intensity for each beam selected 
• Generating collimator shapes from beam intensity for actual delivery 
These steps are usually performed sequentially. However, some can be combined together 
to improve the efficiency of the process. 
Accurate imaging plays an important role in radiotherapy planning. 3D information of the 
tumor mass and affected region is obtained through computed tomography (CT) scan. 
Other methods like magnetic resonance imaging (MRI) may also be used to fuse with CT 
scan to allow radiation oncologist to more accurately identify the location and size of the 
tumor. The International Commission on Radiation Unites and Measurements (ICRU) has 
defined various volumes related to tumor[65]. The gross tumor volume (GTV) is defined 
to be the gross demonstrable volume of the malignant growth, which is generally the tumor 
seen from the CT image. Clinical target volume (CTV), expands GTV to include suspected 




patients personalized characteristics. To account for the uncertainties from both the CT 
imaging and the knowledge of tumor growth, a planning target volume (PTV) is defined to 
include additional margins to ensure adequate coverage of the target. In addition, organs at 
risk (OARs) are also delineated to consider the normal tissue structures whose functionality 
are prone to be damaged by radiation. All these structures are delineated by drawing the 
contours along their boundaries and the volumes are discretized into voxels at the same 
resolution of CT image. Combined with CT values, this volumetric information is stored 
in digital imaging and communications in medicine (DICOM) format for file transfer and 
future treatment planning (fig. 4.2). 
 





The treatment goals for each organ are determined by the radiation oncologists. First, to 
ensure the effectiveness of the treatment, a prescription dose is assigned to cover the PTV 
volume (e.g., > 95%). This is clinician-dependent and may vary across sites.   The radiation 
exposure of normal tissues and critical organs must be kept to minimal. Therefore, dose 
spillage outside PTV should be minimized and the dose falloff should be rapid in all 
directions away from PTV. For OARs, the dose requirements often include maximum dose 
and dose volume limit, which constrains the dose distribution in OARs. For example, the 
volume (or percentage of volume) of an OAR with dose more than 10Gy should be less 
than 1cc (or 90%). Finally, the total dose of radiation is divided into several smaller doses 
over a period of several days, which is called dose fractionation. This procedure maximizes 
the effect of radiotherapy and reduces the toxic effect deposited to healthy tissues. 
Treatment objectives are often determined following common clinical protocols and 
personalized adjustments will be made to tailor patient’s specific needs. The Radiation 
Therapy Oncology Group (RTOG), published more than 300 protocols for different tumor 
sites and radiotherapy delivery techniques. 
The radiation dose is the amount of energy absorbed by tissues per unit of mass and is 
measured in the unit Gray (Gy) with 1 Gy =  1 J/kg . The current dose calculation 
algorithms can be classified into three types: correction-based method, model-based 
method and the Monte Carlo method. Correction-based algorithms use parameters of dose 
measured in water phantoms and modify the data to apply to the patient’s specific 
characteristics. Beam field shapes, irregular surface of the patient and heterogeneity of 
tissue densities are taken into account to calculate the dose. Though these methods are 




methods, however, directly compute the dose by modeling the beam and its interactions in 
the patient. It assumes that any beam hitting on the patient is actually a bunch of small and 
narrow “pencil beams”. Once a pencil beam hits the surface of the patient, dose will be 
deposited and spread out under the surface. The dose distribution of the pencil beam is 
often estimated by Monte Carlo simulation and is referred to as dose kernel. Then the dose 
of each voxel is calculated by the integration of dose deposited from all the surrounding 
pencil beams to that voxel, which is also called superposition. As inhomogeneities exists 
in real patients, different anatomical structures have different photon attenuation and dose 
absorption. Therefore, the dose distribution of each pencil beam is corrected based on voxel 
properties (usually CT number) through ray-tracing[68]. Fast convolution-superposition 
methods have been developed [69] and GPU acceleration has been used to speed up the 
superposition calculation[70], which makes them the most widely used algorithms in 
commercial treatment planning systems. The Direct Monte Carlo method, compared to the 
former methods, is the most accurate in terms of dose computation, especially in complex 
situations. The dose distribution of a beam is obtained by creating a large number of 
particles with their attenuation and scattering behavior simulated by computer[71]. To 
reduce errors of simulation, huge number of particles are often simulated which often 
makes the dose calculation time-consuming. Dose calculation plays a critical role in 
radiotherapy treatment planning and its accuracy directly relates to the quality of the plan 





Figure 4.2. The DICOM image showing a case of prostate cancer. Anatomical structures: 
GTV(green), PTV(yellow), Bladder(light blue), Prostatic urethra(pink), Rectum(red), Femoral 
heads(dark blue)  
 
4.1.2 Treatment planning 
Since the publication of Shepard et al. [72], inverse planning of radiotherapy becomes one 
of the most important applications of operations research and various algorithms have been 
designed to solve this problem[73]. Generally, the treatment planning of radiotherapy 
consists of three sequential phases: beam angle optimization (BAO), fluence map 
optimization (FMO), and leaf sequencing (LS). Each process can be optimized separately 
or combined together to solve.  
The BAO problem is to find the best selection of beam angles from which the beams are 
sent off. Beam selection is fundamental to the concept of cross-firing of radiation source. 
A plan with too many beams is time-consuming to deliver and may lead to errors due to its 
complexity. It may also increase the radiation exposure of critical organs. Moreover, BAO 
is very important in cases when the tumor shape is irregular or critical organs wrap around 
the tumor. In practice, usually a candidate set of beam angles is predetermined/chosen by 
the planner. These beam angles, either coplanar or non-coplanar, are often evenly 




optimization of beam angles is combinatorial and computationally difficult to solve. 
Ehrgott et al. presented a minimum cost set covering approach to beam selection. The 
model requires each voxel to be covered by at least one angle and the cost of each beam 
angle is assigned to be proportional to the cost of violating the dose upper bound of OARs 
which that beam pass through[74]. Another way to score each beam is based on its ability 
of delivering more dose to the target without violating dose restrictions on the non-targeted 
regions[75]. Scoring functions are also used in heuristic iterative methods such as local 
search[74, 76, 77], simulated annealing[78, 79], genetic algorithm[80, 81] and particle 
swarm optimization (PSO)[82]. The PSO algorithm starts with a set of particles with each 
represents a selection of beam angles. In each iteration, each particle updates its beam 
selection based on the personal best solution, global best solution and a random shift. As 
iteration increases, the population (called swarm) of particles will converge to a local 
optimal beam selection. BAO problem is very closely related to the FMO problem which 
optimizes the intensities of beams. In all the heuristic algorithms mentioned above, whether 
mentioned explicitly or not, essentially solve the two problems consecutively. The 
combined models will be discussed together with FMO in the next paragraph. 
 
Figure 4.3. (a) Fluence map optimization with beamlet intensities represented in grayscale matrices. 





The core problem of treatment planning is to optimize the beam intensities so that a 
clinically satisfactory plan will be achieved (fig. 4.3(a)). To model beam intensities, the 
beam is discretized into beamlets or bixels whose size is determined by the MLC leaf 
configuration. Let 𝑑𝑖𝑗𝑘 denote the dose received by voxel i from beamlet j of beam k,  and  
𝐷 = (𝑑𝑖𝑗𝑘)   the dose matrix by indexing rows by i  and columns by (j, k) . Various 
optimization models have been developed to solve the FMO problem. Some models try to 
minimize the deviation of dose received by the target from the prescription dose and the 
overdose of organs at risk or normal tissues. The problem can be formulated as[84] 
min
𝑥≥0
ω𝑃𝑇𝑉‖DPTVx − PrDose‖p + ω𝑂𝐴𝑅‖(DOARx − OARUB)+‖p + ω𝑁𝑇‖(DNTx − NTUB)+‖p (4.1.1) 
where x  is the beamlet intensity or beamlet weight and PrDose , OARUB , NTUB  are 
prescription dose, dose upper bound on OARs and dose upper bound on normal tissues 
respectively. Here (∙)+ = 𝑚𝑎𝑥 {0, ∙} and ‖∙‖p  is vector p-norm. ω𝑃𝑇𝑉 , ω𝑂𝐴𝑅 , and ω𝑁𝑇 
are weight factors of each structures reflecting the importance of each objective. When p =
1 or ∞, (4.1.1) becomes a linear program[85]. When p = 2, (4.1.1) becomes one of the 
most prevalent weighted least squares model[86] that is often used in clinical planning in 
practice. Since both linear and quadratic program are convex, they can be solved to 
optimality rapidly. Another type of objective function is based on radiobiological effects 
produced by the dose distribution. Tumor control probability (TCP), which characterizes 
the response of target to radiation, is a commonly used in the radiobiological models. A 
Poisson-based TCP function[84] is  
𝑇𝐶𝑃 = ∏ 𝑒𝑥𝑝(−(𝑂/𝑚𝑇)𝑒𝑥𝑝(−𝑟𝑑𝑖))
𝑚𝑇




where 𝑚𝑇 is the number of equivolume voxels in the target, 𝑟 is the radio sensitivity of the 
tumor clonogens, 𝑂 is the total number of clonogens and 𝑑𝑖 is the dose to voxel 𝑖. Based 
on TCP, Niemierko introduced the concept of tumor equivalent uniform dose (EUD), 
which assumes that two dose distributions are equivalent if they have the same tumor 
control probability[87]. The EUD is defined as 






∑ e−adimi=1 )                  (4.1.3) 
where 𝑚 is the number of voxels and 𝑎 is a structure dependent parameter that relates to 
the radiation response. The generalized equivalent uniform dose (gEUD), which is defined 
as  








                    (4.1.4) 
extends the definition to normal tissues[88]. Moreover, Choi and Deasy proved that TCP 
is strictly concave and gEUD is convex when a ≥ 1 and concave when a < 1[89]. Many 
models developed their objective functions from TCP or gEUD[90, 91] and such 
biological-based optimization appears promising when compared to the least square 
minimization[92]. The constraints of FMO models often include non-negativity of beamlet 
intensity, upper and lower bound on the dose to tumor and OARs. One of the constraints 
appeared in RTOG is the dose volume constraint (DVC). These constraints differ from 
max/low point dose constraints in that they constrain the dose received by certain volume 
or percentage of volume of a structure. One approach is to divide the structure into high-
dose and low-dose volume based on the distance to the beam isocenter and set different 




al., use the concept of conditional value-at-risk (CVaR) to develop an approximation of 
DVCs[94]. CVaR models give a convex approximation to the standard optimization with 
dose volume constraints, which is proven to be non-convex[95], so that the optimization 
can be solved quickly. By introducing binary variables, dose volume constraints can be 
modeled as follows 
         ∑ 𝐷𝑝,𝑖𝑗𝑥𝑖𝑗ij ≤ α PrDose y𝑝
α + OARUBzp, 𝑝 ∈ 𝑂𝐴𝑅      (4.1.5) 
     ∑ 𝑦𝑝
α
𝑝∈𝑂𝐴𝑅 ≥ β|𝑂𝐴𝑅|,      (4.1.6) 
     yp
α + zp = 1, p ∈ OAR      (4.1.7) 
where yp
α and zp are binary variables and 𝑥𝑖𝑗 is the intensity of beamlet 𝑗 from beam 𝑖 [96, 
97]. OARUB is the dose upper bound on all OAR voxels and |𝑂𝐴𝑅| is the total number of 
OAR voxels. So (4.1.5) - (4.1.7) ensures that at least 100β% of OAR voxels receive dose 
no greater than 100α% of prescription dose[96]. In addition, binary variables can also be 
used to represent beam selection in the combined FMO plus BAO model[98, 99]. For each 
beamlet 𝑗 from beam 𝑖, let yi be the binary variable indicating the on/off of a beam in 𝐵. 
Lee et al [96] formulate the beam selection, along with the fluence map optimization, as 
 ∑ 𝑦𝑖𝑖∈𝐵 ≤ Bmax and xij ≤ Miyi,  ∀𝑗 ∈ 𝐵𝑖, 𝑖 ∈ 𝐵  (4.1.8) 
Here Bmax  is the maximum number of beam allowed to use and Mi  is the maximum 
intensity allowed for each beamlet 𝑗  from beam 𝑖 . Mixed-integer programming (MIP) 
models provide high flexibility in modeling complex constraints and objectives and in turn 




more difficult to solve. With special branch-and-bound strategies and cuts implemented, 
good quality solutions can be obtained in a reasonable time[97]. From clinical perspective, 
there are often multiple criteria required for the delivery of radiation therapy[73]. 
Therefore, FMO problem is naturally a multi-objective optimization problem that involves 
the trade-off among different clinical objectives. A solution is called pareto-optimal if we 
cannot improve any treatment objective without deteriorating other objectives. Models 
introduced so far use weighted sum of different objectives as a single objective function, 
which is a widely used strategy called scalarization. Another approach, called 
lexicographic optimization (LO) (or pre-emptive programming), optimizes each objective 
sequentially based on the clinical priority of objectives. Moreover, higher priority objective 
functions, which have been optimized, will be constrained to their achieved values when 
optimizing lower priority objectives[100, 101]. Scalarization and lexicographic 
optimization are mathematically equivalent and can be switched between each other 
through Lagrangian multipliers[102].  
Once the intensity profile of each selected beam is found, leaf sequencing (LS) algorithms 
are used to create MLC deliverable shapes, which is called segment or aperture, from the 
optimized fluence map. The fluence map obtained after FMO can be seen as a real 
nonnegative matrix 𝐼. Very often 𝐼 will first be “smoothed” so that entries in 𝐼 will have 
values at discrete intensity levels[103, 104]. Smoothing procedure makes the realization of 
the fluence map easier both mathematically and practically. Now the LS problem is to find 
a set of binary matrices 𝐾 such that 
𝐼 = ∑ α𝑘𝑌
𝑘




where 𝑌𝑘 ∈ 𝐵𝑚×𝑛 is called shape matrix with 𝑚 rows representing the leaf pairs of MLC 
and 𝑛 columns representing the number of beamlets for each leaf pair. α𝑘 ≥ 0 is called the 
monitor unit (MU) of the aperture 𝑘. As each row represents the opening of a leaf pair, the 
shape matrix 𝑌𝑘 must possess the consecutive-ones (C1) property, which says that entries 
with value 1 in each row should be consecutive (fig. 4.3(b)). By (1.2.9), one can either 
minimize the total beam-on-time (BOT), DT(α) ≔ ∑ α𝑘𝑘∈𝐾  or minimize the total number 
of apertures, D𝐶(α) ≔ |{αk: αk > 0}| . Assume the average time needed for MLC to 
change aperture shape is τ, then one can also minimize the total treatment time 𝑇T(α) ≔
DT(α) + τDC(α). DT problem can be solved by the sweep algorithm proposed by Bortfeld 
et al.[105]. The optimality of this algorithm is proven by transforming it into a network 
flow problem and can be solved in polynomial time[106]. In practice, more complex 
hardware constraints other than C1 constraint are needed based on the type of MLC. 
Interleaf motion constraints require that the opening of two neighboring rows should at 
least overlap with one column. Leaf width constraints requires that the opening of each row 
should be at least a constant value δ > 0. Since most MLC systems use tongue-and-groove 
joints between adjacent leaf pairs, the tongue leaves will cause smaller radiation than 
groove leaves, which makes (4.1.9) not accurate in real delivery. Therefore, tongue-and-
groove constraints is required to ensure that the opening of a column in the shape matrix 
be at least two rows long. Baatar et al. proved that DT problem with interleaf and width 
constraint can be solved in O(nm2) time[107]. Siochi developed a rod-pushing algorithm 
that solves the DT with tongue-and-groove correction[108]. Compared to DT problem, 𝐷𝐶 
problem is proven to be NP-hard[107]. Some heuristic methods have been developed to 




There are some shortcomings of the traditional two-step optimization framework, i.e. doing 
FMO and LS sequentially. First, as leaf sequencing often requires smoothing of the fluence 
map, there is often degradation of plan quality between FMO and LS solutions. Moreover, 
lots of apertures will be generated if the fluence map is complex, which will lead to long 
treatment time. Direct aperture optimization (DAO) method, which combines FMO and 
LS together, has been developed to address these issues. The solution of DAO is already 
deliverable and the total treatment time can be directly optimized in the DAO model. DAO 
directly optimized the shapes and intensities of apertures at the same time. However, the 
difficulties of DAO are that the aperture shape generation and optimization. And there are 
mainly three different methods to achieve it. The first type of models optimizes aperture 
shapes by performing small leaf position changes using heuristic algorithms. An initial set 
of apertures are predetermined to the beam’s eye view (BEV) of the target. Shepard et al. 
developed a method to update the leaf positions using simulated annealing approach so that 
the objective value is improved[112]. In their method, the total number of apertures is fixed 
before the optimization. The second type of models, which is similar to the first one, 
considers the leaf positions as optimization variables and optimize them using gradient 
descent method. Both the objective function and its gradient are approximated as functions 
of leaf positions[113]. Such leaf refinement methods have been used in some commercial 
treatment planning systems(Pinnacle TPS, Philips Radiation Oncology Systems, 
Fitchburg, WI[114]). The last type of models adds apertures iteratively using column 
generation method. New apertures, which are promising to improve the objective value, 
are created by solving a pricing problem and added to the master problem to re-optimize 




In Section 4.2, we summarize the contribution of treatment planning in this thesis. We first 
solve the problem of isocenter selection for radiation beams. This problem, which is rarely 
discussed in literature, is very important for improving plan quality of radiotherapy. Then 
we propose a multi-objective direct aperture optimization model that includes most 
commonly used clinical planning goals. The optimization is solved in a pre-emptive way 
such that treatment goals are optimized based on the priority that is determined by 
clinicians and/or that they are most suitable for each individual patient. Coupled with the 
optimization model, a novel heuristic column generation approach is designed to create 
new aperture shapes that can be added to improve the objective values. This column 
generation approach, which does not rely on beamlet dose calculation, efficiently produces 
large number of promising apertures so that the master multi-objective optimization 
problem can generate feasible deliverable plans in a short period of time. Moreover, we 
further integrate the beam selection into this direct aperture optimization framework. 
Hence, this work presents the first treatment planning model that optimizes beam angle, 
aperture shape and aperture intensity in a single procedure. We test the model for 15 real 
patient cases including 5 prostate, 5 lung and 5 intracranial cases. For all cases, our model 
can efficiently generate clinically acceptable and readily deliverable plans in a reasonable 
time. 
 
4.2 Methods to advance treatment planning and applications to Cyberknife 
The content of this section is based on three submitted manuscripts[12-14] 




Single-isocenter plans are often used in radiation therapy treatment. Plans with multiple 
isocenters increase the complexity of the treatment and often use more MUs to deliver[96]. 
However, increasing the number of isocenters can greatly improve dose conformity of the 
target, especially for treating non-spherical, irregular, or large tumors that cannot be 
covered by the collimator[117]. Multiple-isocenter plans can be achieved by optimizing 
the location of isocenters[98]. We propose a general-purpose mathematical model for the 
optimization of isocenter locations.  
Although the exact dose distribution produced by a single isocenter depends on the beam 
angle selection, it is nearly spherical and homogeneous around the isocenter for a LINAC 
system and can be approximated by a set of ellipsoids[118]. Since the dose fall-off is a 
function of distance from the isocenter, we can expect a highly conformal plan by choosing 
a set of ellipsoids that cover all target points and have minimum excess volume. Generally, 
this problem can be stated as an optimization problem. Suppose there is a set of points in 
V ⊂ ℝ3. Given an integer 𝑁𝑐 ≥ 1, find 𝑁𝑐 ellipsoids 𝐸1, . . . 𝐸𝑁𝑐 such that 𝑉 ⊂ ∪𝑖=1
𝑁𝑐 𝐸𝑖  and 
the volume 𝑉𝑜𝑙(∪𝑖=1













2 ≤ 1}, then the problem can be formulated as 
                        (ISO)              Min      𝑉𝑜𝑙(∪𝑖=1
𝑁𝑐 𝐸𝑖) 














≤ 1 + 𝑀 ∙ 𝑦𝑣𝑖,         ∀𝑣 ∈ 𝑉       
              ∑ 𝑦𝑣𝑖
𝑁𝑐
𝑖=1 = 1,   ∀𝑣 ∈ 𝑉   




When 𝑁𝑐 = 1, (ISO) becomes the classic minimum enclosing disk problem[119]. In the 





∗) will be chosen as the isocenter. Mathematically, solving (ISO) is not easy. 
First, computing the volume of a union of ellipsoids/balls is complicated[120]. Second, 
even though we can find an explicit form to represent the volume of the union of ellipsoids, 
it is a nonlinear mixed-integer program and computationally hard to solve. Lee et al 
designed an integer programming approach to optimize the isocenter selection. The 
algorithm optimizes over all potential voxels and uses the quality of the plan outcome as 
objective functions to drive the selection and location of the isocenters[96]. 
In this work, we develop a heuristic approach to solve (ISO) to obtain a solution that results 
in highly conformal plans. Based on our experiment, we observed that it is not necessary 
to obtain an optimal solution as the isocenters for most of the cases. A near-optimal solution 
can already greatly improve the dose conformity as we can choose wisely the beam angles 
and optimize the MLC shape.  
In practice, our first task is to determine 𝑁𝑐, the number of isocenters best suited for the 
tumor, before we can solve (ISO). We assume that the dose distribution of a single isocenter 
is spherical, we can obtain good dose conformity if the target also has spherical shape. 
Therefore, we can identify the spherical shaped parts of the target and the number of 
isocenters should match the number of such parts. We know that the target is discretized 
into voxels in CT space. We define a z (x or y)-direction-slice as the plane with all the 
voxels having the same z (x or y) value. If the target is a ball, the number of voxels in any 
direction-slices will gradually increase from zero to a maximum value and then decrease 




to negative. In figure 4.4, we showed a schwannoma tumor which is tiny but irregular. For 
each of the anatomical direction, a voxel vs. slice curve is fitted. When a target is irregular, 
there must exist a direction (sagittal in this case) where there are multiple local maxima in 
the voxel-slice curve. Each peak of the curve represents a ball shaped part of the target. 
Therefore, the number of ball shaped parts in that direction is determined by the number of 
peaks 𝑝𝑥 (𝑝𝑦or 𝑝𝑧) in the curve.  Then the maximum value p
∗ = 𝑚𝑎𝑥{𝑝𝑥 , 𝑝𝑦, 𝑝𝑧} will be 
used as the number of isocenters. For some highly irregular shaped targets, p∗ can be large. 
To balance plan complexity and dose conformity, we set the maximum number of 
isocenters to be 3. So 𝑁𝑐  =  max{𝑝
∗, 3}. Among the 15 cases we tested, all the prostate 
tumors are ball shaped and the heuristic algorithm returns 𝑁𝑐 = 1. Lung tumors are often 
big and irregular, in 4 out of 5 cases,  𝑁𝑐 is greater than 1. For the intracranial cases, the 
tumors are tiny yet irregular, 3 out of 5 cases have 𝑁𝑐 greater than 1. (fig. 4.5) 
 
Figure 4.4. A schwannoma tumor case. Top: The shape of the tumor is plotted in transversal, 
sagittal and coronal view respectively. Each column of dots in the figure represents a z (x or y)-




Once 𝑁𝑐 is determined, we need to determine the location of isocenters. When 𝑁𝑐 = 1, a 
single-isocenter plan is preferred and the center of mass of the target will be used as the 
isocenter. When 𝑁𝑐 = 2 or 3, however, the location of the isocenters in (ISO) can be 
potentially anywhere in the space, which makes it hard to solve. A possible solution is 
using the classic K-means clustering algorithm[121] to cluster target voxels into 𝑁𝑐 
clusters. However, the result of K-means algorithm is not satisfactory as it cannot capture 
the highly irregular shape of the target. Instead, we identify a set of good candidate 
locations L and the isocenters will be chosen from it by solving an optimization problem. 
 
Figure 4.5. From left to right, prostate tumor, lung tumor, schwannoma tumor; number of target 
voxels in each slice (blue dot), fitted voxel vs. slice curve (solid red) and its derivative (dotted 
black). 
 
Suppose p∗ = 𝑝𝑥, then for each x-direction-slice, the center of mass of target voxels in 
each x-direction-slice is calculated and included in L. Define S as the set of surface points 
of the target and  dij as the distance between a location i ∈ L and a point j ∈ S . Intuitively, 
a location will be chosen if the average distance between all surface points to that location 
is small. Therefore, we formulated an integer program to find such locations so that the 




                                    (ISOFLP)      Min       ∑ ∑ dij𝑥𝑖𝑗j∈ Si∈L                
                           s. t.        ∑ xiji∈L = 1,             ∀𝑗 ∈ 𝑆 
                      xij ≤ yi,                    ∀𝑖 ∈ 𝐿,  ∀𝑗 ∈ 𝑆 
              ∑ yii∈L ≤ Nc,             ∀𝑖 ∈ 𝐿 
                                                         xij, 𝑦𝑖 ∈ {0,1}              ∀𝑖 ∈ 𝐿,  ∀𝑗 ∈ 𝑆    
This problem is a facility location problem with no cost of opening facilities but a capacity 
on the number of facilities opened[122]. It is an integer program that is often used to solve 
the placement of facilities to best meet the demand of customers. Though integer programs 
are generally computationally difficult to solve, (ISOFLP) usually takes less than a minute 
to get optimal solution for the cases we tested. The solution of (ISOFLP) is used as the 
isocenters for our plan(fig. 4.6).  
 
 
Figure 4.6. Set of potential candidate locations (blue dots); and selection of isocenter locations by 




4.2.2 Multi-objective direct aperture optimization 
The main goal of radiation therapy is to deliver adequate dose to the tumor site while 
sparing as much as possible the normal tissues around tumor. The quality of a plan is 
evaluated by several criteria including biological functions (TCP, EUD, gEUD, etc.) and 
dosimetric functions (mean dose, homogeneity, etc.). We list below the criteria considered 
in this work and the corresponding definition. 
• Coverage: the percentage of target volume receiving dose higher than prescription 
dose 
• Max dose: the maximum dose allowed in tumor or OARs 
• Mean dose: the average dose received in tumor or OARs 
• Dose volume histogram (DVH): a frequency distribution of dose values within 
tumor or OARs  
• Conformity: The conformity index (CI) is defined as ratio of volume enclosed by 
prescription isodose surface to the target volume enclosed by the same surface. It 
is a measure of how well the prescription isodose surface conforms to the target. 
The ideal value is 1. 
• Homogeneity: The homogeneity index (HI) is defined as HI =
Dmax
Dmin
, where Dmax 
is the maximum dose received by the target (“max dose”) and Dmin is the minimum 
dose received by the target (“min dose”). It is a measure of uniformity of the dose 
distribution in target and should close to 1. 





In practice, different patients have different clinical conditions. Radiation therapy, which 
is a multi-objective optimization problem, can be personalized to favor patient’s own 
characteristics. For some patients, the best plan could be one which has full coverage of 
tumor without regard to the normal tissue receiving high dose. For other patients, whose 
critical structures are close to the tumor, doctors may prefer a plan with a slight underdose 
to the tumor while ensuring low dose to critical structures. Therefore, the optimization 
model should provide high flexibility for modification so that the “best” possible plan can 
be obtained. Compared to the traditional scalarization method, the lexicographic 
optimization method (LO) does not need the weighting factors of the objectives and doctors 
can directly place the optimization steps in order of clinical priority. Moreover, the solution 
of each step is guaranteed feasible and the objective of each step can only be compromised 
by a slight relaxation in later steps. Doctors can easily identify the trade-offs between 
different objectives and balance on conflicting goals[123].  
In this thesis, we proposed a lexicographic linear direct aperture optimization model 
(LLDAO) using column generation algorithm. All objectives and constraints are linear in 
LLDAO and different objectives enter the optimization sequentially in order of clinical 
priority. At each step, the objective function is optimized using apertures generated until 
last step. New apertures will be generated using column generation when the current 
objective value is not clinically acceptable. This procedure will be fully automatic once the 
order of objectives is determined. Moreover, the final solution of LLDAO is clinically 
deliverable as it uses apertures in the optimization. The complete LLDAO procedure is 




The optimization will start with an initial set of apertures which are generated from the 
projection of PTV voxels of each beam angle. At each step, one of the objectives will be 
optimized with PTV and OAR dose upper bound and with objective functions from 
previous steps constrained. For dose-volume constraints, we adopted the CVaR constraints 
first introduced in [94]. Instead of bounding the minimum or maximum of a tail of the 
DVH, CVaR constraints bound the mean value of the tails. Let 𝐴 denote the set of all 
candidate apertures, Dp,a be the dose coefficient of aperture a to voxel p and xa be the 











where 𝑃𝑇𝑉𝑄𝛼 is the maximum dose received by at least 100(1 − 𝛼)% of PTV voxels. So 





∑ 𝑚𝑎𝑥 (0, 𝑃𝑇𝑉𝑄𝛼 − ∑ 𝐷𝑝,𝑎𝑥𝑎
a∈A
)  ≥  𝐿𝛼
𝑃∈𝑃𝑇𝑉
 









𝛼 ≥ 𝑃𝑇𝑉𝑄𝛼 − ∑ 𝐷𝑝,𝑎𝑥𝑎a∈A   , p ∈ PTV 
𝑡𝑃𝑇𝑉𝑄𝑝




Such linear transformation will keep the optimization in LLDAO as a linear program 
without introducing nonlinear or integer component. To optimize conformity and achieve 
steep gradient around PTV, we introduce the shell structures around PTV and minimize 
the dose to them[96, 98]. The voxels in a shell structure locate in a certain distance to the 
surface of PTV. For example, SHELL_2MM is defined as the voxels 2mm away from 
PTV. The shell structures are treated as an OAR and optimizing the dose to it is proven to 
be effective to reduce conformity index[98]. In our work, we use SHELL_2MM and 




Figure 4.7. LLDAO process map. New apertures will be generated using column generation 
algorithm. Then the dose is calculated and added to the model to re-optimize. The process will go 
to next step when the current objective value is clinical acceptable or no apertures can be generated 





Below we will show an efficient process of LLDAO that includes commonly used 
objectives in radiation therapy.  
Step 1 (PTV min feasibility): 
       Min ∑ 𝑆𝑙𝑎𝑐𝑘𝑝𝑝∈𝑃𝑇𝑉                      (4.2.1) 
     s.t.    ∑ 𝐷𝑝,𝑎𝑥𝑎a∈A + 𝑆𝑙𝑎𝑐𝑘𝑝 ≥ 𝑃𝑇𝑉𝑙𝑏, p ∈ PTV          (4.2.2) 
∑ 𝐷𝑝,𝑎𝑥𝑎a∈A ≤ 𝑃𝑇𝑉𝑢𝑏   , p ∈ PTV     (4.2.3) 
∑ 𝐷𝑝,𝑎𝑥𝑎a∈A ≤ 𝑂𝐴𝑅𝑢𝑏  , p ∈ OAR     (4.2.4) 
           0 ≤ 𝑥𝑎 ≤ 𝑀𝑎𝑥𝑀𝑈 , 𝑎 ∈ 𝐴      (4.2.5) 
                       𝑆𝑙𝑎𝑐𝑘𝑝 ≥ 0 , p ∈ PTV      (4.2.6) 
where 𝑆𝑙𝑎𝑐𝑘𝑝 is the underdose value of voxel p.  𝑃𝑇𝑉𝑙𝑏, 𝑃𝑇𝑉𝑢𝑏 are the lower and upper 
dose limit on PTV voxels and 𝑂𝐴𝑅𝑢𝑏 is the upper dose limit on OAR voxels. 𝑀𝑎𝑥𝑀𝑈 is 
the maximum MU allowed for an aperture. When ∑ 𝑆𝑙𝑎𝑐𝑘𝑝𝑝∈𝑃𝑇𝑉 = 0 , there is no 
underdose for all PTV voxels. However, the initial aperture set will not guarantee the 
optimal objective value to be zero if constrained by (4.2.2)-(4.2.4). Therefore, new 
apertures should be generated until ∑ 𝑆𝑙𝑎𝑐𝑘𝑝𝑝∈𝑃𝑇𝑉  is zero. 
 
Step 2 (PTV (1-𝛂)% coverage): 









                 s.t.           (4.2.3) − (4.2.5) from previous steps 
        ∑ 𝐷𝑝,𝑎𝑥𝑎a∈A ≥ 𝑃𝑇𝑉𝑙𝑏, p ∈ PTV             (4.2.8) 
               𝑡𝑃𝑇𝑉𝑄𝑝
𝛼 ≥ 𝑃𝑇𝑉𝑄𝛼 − ∑ 𝐷𝑝,𝑎𝑥𝑎a∈A ,  p ∈ PTV           (4.2.9) 
          𝑡𝑃𝑇𝑉𝑄𝑝
𝛼 ≥ 0, p ∈ PTV                (4.2.10) 
          𝑃𝑇𝑉𝑄𝛼 ≥ 0, p ∈ PTV                  (4.2.11) 
In step 2, we directly maximize the lower α- CVaR of the PTV to achieve adequate dose 
coverage of PTV. From (4.2.7), we see that the lower α- CVaR is a lower bound of 𝑃𝑇𝑉𝑄𝛼. 
So (1-α)% PTV coverage will be guaranteed if (4.2.7) is greater than the prescription dose. 
Again, new apertures will be generated when PTV coverage is not satisfied. 
 
Step 3 (Optimize Conformity): 





𝑃∈𝑆𝐻𝐸𝐿𝐿             (4.2.12) 
          s.t.      (4.2.3) − (4.2.5), (4.2.8) − (4.2.11) from previous steps 





𝑃∈𝑃𝑇𝑉 ≥ 𝑃𝑇𝑉𝐷𝑜𝑠𝑒𝛼        (4.2.13) 
         𝑡𝑆ℎ𝑒𝑙𝑙𝑄𝑝
𝛼 ≥ ∑ 𝐷𝑝,𝑎𝑥𝑎𝑎∈𝐴 −  𝑆ℎ𝑒𝑙𝑙𝑄
𝛼 , p ∈ SHELL  (4.2.14) 
          𝑡𝑆ℎ𝑒𝑙𝑙𝑄𝑝




Here, 𝑃𝑇𝑉𝐷𝑜𝑠𝑒𝛼 is the optimal objective value from step 2 with a small relaxation. For 
most cases we tested, plans from step 2 will satisfy PTV coverage and (4.2.7) is greater 
than prescription dose. So 𝑃𝑇𝑉𝐷𝑜𝑠𝑒𝛼 is set to be the prescription dose. Although the shell 
structure is treated as an OAR in the optimization, the big difference between shell and 
OAR is that we cannot set dose limit on shell structures as it depends on tumor 
characteristics and the value of prescription dose. We can minimize either the total dose or 
the max dose to shell voxels to control dose spillage. Here we propose another perspective 
to the optimization of conformity. Suppose we want to get a plan with conformity index 
less than a reference value of 1.2. By the definition of conformity index, we know that at 
most 0.2|𝑃𝑇𝑉| shell voxels can have dose larger than the prescription dose. This can be 




of shell voxels can have dose larger than prescription dose. Although this is only a 
necessary condition for CI ≤ 1.2, empirically, it is very effective in reducing CI. Compared 
to minimizing total dose, CVaR formulation targets voxels with large dose so that CI can 
be reduced much faster. 
 
Step 4 (minimize OAR mean dose): 
Min   ∑ 𝑑𝑝𝑃∈𝑂𝐴𝑅         (4.2.16) 
     s.t.   (4.2.3) − (4.2.5), (4.2.8) − (4.2.11), (4.2.13) − (4.2.15) from previous steps 









∑ 𝐷𝑝,𝑎𝑥𝑎𝑎∈𝐴 = 𝑑𝑝, p ∈ OAR     (4.2.18) 
Here, 𝑆ℎ𝑒𝑙𝑙𝑢𝑏 is the optimal objective value in step 3 with a small relaxation. One of the 
advantages of optimizing CI before OAR is that the conformal plan from step 3 is very 
likely to have low dose in the surrounding OARs. For OARs that need further reduction of 
dose, they are added in step 4 sequentially based on clinical priority and their mean dose is 
minimized. In our analysis, OARs are added from the closest to the farthest to the surface 
of PTV. 
 
Step 5 (Reduce Total MU): 
Min   ∑ 𝑥𝑎𝑎∈𝐴          (4.2.19) 
s.t.   (4.2.3) − (4.2.5), (4.2.8) − (4.2.11), (4.2.13) − (4.2.15), 
(4.2.17)  −  (4.2.18) from previous steps 
             ∑ 𝑑𝑝𝑃∈𝑂𝐴𝑅 ≤ 𝑂𝐴𝑅_𝑇𝑜𝑡𝑎𝑙_𝐷𝑜𝑠𝑒, p ∈ OAR   (4.2.20) 
Again, 𝑂𝐴𝑅_𝑇𝑜𝑡𝑎𝑙_𝐷𝑜𝑠𝑒 is the optimal objective value in step 4 with a relaxation. Step 5 
addresses the trade-off between plan quality and plan complexity. Plans with longer 
treatment time are subject to more leakage radiation, which increases the total body integral 
dose. For all LINAC systems, the treatment time of a plan relates to the number of beams, 
apertures and total MU. We will discuss the beam selection in section 4.2.4 and focus on 
total MU here. Though the complexity of a plan depends on the complexity of the 




significantly reduced[125]. The traditional two-step optimization method often observes 
increase of total MU after leaf sequencing and is difficult to control during the 
optimization. Direct aperture method, by optimizing step 5, can minimize directly the total 
MU to generate highly efficient plans. The problem of direct aperture method, which is 
rarely mentioned in the literature, is the difficulty in keeping the aperture MU from very 
small values. Since direct aperture models are often solved by convex optimization method 
constrained only on the non-negativity of aperture MU, the optimal solution often has some 
apertures with very small MU (e.g. less than 10). Apertures with small MU are hard to 
deliver in practice and are subject to large errors. But simply eliminating these apertures 
will cause underdose to the target. Therefore, a strict positive lower bound on MU of every 
used aperture should be included. To solve this issue, we proposed a mixed-integer 
program based on step 5 to force the MU of all selected apertures greater than a minimum 
value. 
 
Step 5’ (Reduce Total MU + MinMU lower bound): 
Min   ∑ 𝑥𝑎𝑎∈𝐴         (4.2.21) 
s.t.   (4.2.3) − (4.2.5), (4.2.8) − (4.2.11), (4.2.13) − (4.2.15), 
(4.2.17)  − (4.2.18), (4.2.20) from previous steps 
𝑥𝑎 ≤ 𝑀𝑎𝑥𝑀𝑈 𝑦𝑎 , 𝑎 ∈ 𝐴     (4.2.22) 




𝑦𝑎 𝑏𝑖𝑛𝑎𝑟𝑦, 𝑎 ∈ 𝐴            (4.2.24) 
where 𝑦𝑎  is a binary variable and equals 1 if aperture 𝑎  is selected. 𝑀𝑖𝑛𝑀𝑈  is the 
minimum MU allowed for an aperture. Step 5’ is a mix-integer program and column 
generation cannot be applied. So total MU will first be minimized to a satisfactory value 
in step 5 and step 5’ serves as a filtering step right after that. 
In addition to these 5 objectives, other linear objectives can also be added into LLDAO. 
For example, we can minimize the max dose to OARs, minimize homogeneity index or 
minimize maximum MU allowed for an aperture.  
 
4.2.3 Column generation 
To successfully implement the LLDAO model, we developed an efficient column 
generation algorithm to create new apertures. All column generation algorithms developed 
in the past need to solve a pricing problem involving the dose coefficient 𝐷𝑝,𝑎 , which is 
the dose per unit monitor to voxel 𝑝 from aperture 𝑎. It is assumed that the dose of an 
aperture equals the sum of dose of beamlets inside that aperture, i.e. 𝐷𝑝,𝑎 = ∑ 𝐷𝑝,𝑖𝑖∈ 𝑎 , 
where 𝐷𝑝,𝑖  is the dose coefficient of beamlet 𝑖 to voxel 𝑝. However, this assumption is 
generally not true in real practice especially when an aperture has irregular shape. Some 
methods have been proposed to address this issue. For example, a correction factor 𝛾𝑎 is 
used for each aperture so that 𝐷𝑝,𝑎 = 𝛾𝑎 ∑ 𝐷𝑝,𝑖𝑖∈ 𝑎  [115]. Others decompose 𝐷𝑝,𝑎  into 2 
parts, 𝐷𝑝,𝑎 = ∑ 𝐷𝑝,𝑖𝑖∈ 𝑎 + 𝜀 ∑ 𝐷𝑝,𝑖𝑖∉𝑎 , where 𝜀 is the transmission factor of the dose from 




correction methods are still not satisfiable to compensate for the discrepancy between 
beamlet solution and aperture solution. For many deliverable plans we tested, huge 
underdose and conformity/homogeneity degradation are observed by just changing from 
beamlet-based dose calculation to aperture-based dose calculation (fig. 4.8). Such 
degradation cannot be removed by multiplying a constant scaling factor. We believe the 
discrepancy comes from the dose calculation algorithm. The dose scattering effect of a 
beamlet, when it is calculated for an aperture, is smaller than the effect which is calculated 
when only this beamlet open. This explains why the aperture-based dose is smaller than 
beamlet-based dose and why the degradation ratio increases with the increase of beamlet-
based dose for OAR voxels (fig. 4.9). 
 
 
Figure 4.8. A prostate case solved by traditional two-step method. After leaf sequencing, dose is 
calculated using 2 different methods. Beamlet-based (solid): the dose of an aperture is calculated 
as the summation of each beamlet dose; Aperture-based (dotted): the dose of an aperture is directly 
calculated using pencil beam algorithm. The comparison of DVH shows huge underdose of the 





Figure 4.9. Dose degradation of aperture-based dose calculation of 4 structures. For each voxel, 
the ratio of aperture-based dose(APT) and beamlet-based dose(BLT) is calculated. 
 
Therefore, using the “true” aperture dose in treatment planning is very important to 
guarantee the quality of the optimized plan and reduce error in QA process. However, this 
create a big trouble for solving the pricing problem to generate new apertures. No matter 
what master problem we use, the pricing problem must use the dose coefficient 𝐷𝑝,𝑎 of the 
new aperture 𝑎 , which becomes unknown without using beamlet dose (i.e. 𝐷𝑝,𝑎 =
∑ 𝐷𝑝,𝑖𝑖∈ 𝑎 ). To solve this issue, we proposed a novel heuristic pricing problem 
(corresponding to LLDAO master problem) that generate new apertures efficiently. This 
algorithm 
1) Does not need any dose information (𝐷𝑝,𝑎 or 𝐷𝑝,𝑖) when generating apertures; 





3) Creates multiple apertures in a single run to accelerate the optimization; 
4) Saves time on dose calculation. No need to calculate beamlet dose. 
In this column generation algorithm, the master problem can be any of the optimization 
problems in the LLDAO model. However, the corresponding pricing problems, which is 
to find new apertures, are of the same form. Precisely, the coefficient of variable 𝑥𝑎 in the 
constraints is 𝐷𝑝,𝑎. Then the reduced cost of an aperture 𝑎 is given by  
𝑅(𝑎) = 𝑐𝑎 − ∑ (λ𝑝
1 + λ𝑝
2 + λ𝑝
3)𝐷𝑝,𝑎𝑝∈𝑃𝑇𝑉 − ∑ 𝜋𝑝𝐷𝑝,𝑎𝑝∈𝑆ℎ𝑒𝑙𝑙 − ∑ (μ𝑝 +  τ𝑝)𝐷𝑝,𝑎𝑝∈𝑂𝐴𝑅    (4.3.1) 
where λ𝑝
1 ≥ 0, λ𝑝
2 ≥ 0, λ𝑝
3 ≤ 0 are the dual variables corresponding to PTV lower bound 
constraints (4.2.8), PTV (1 − 𝛼)% coverage constraints (4.2.9) and PTV upper bound 
constraints (4.2.3). 𝜋𝑝 ≤ 0 are the dual variables corresponding to Shell CVaR constraints 
(4.2.14) and μ𝑝 ≤ 0, τ𝑝 ≤ 0 are the dual variables corresponding to OAR upper bound 
constraints (4.2.4), OAR dose constraints (4.2.18). 𝑐𝑎 is the cost coefficient of aperture 𝑎 
in the objective function. Since the maximization of PTV (1-α)% coverage can be changed 
to a minimization problem by negating the sign of the objective function, all linear 
programs in LLDAO are minimization problems. So the pricing problem is to find 
apertures such that 𝑅(𝑎) < 0, and can be written as 
𝐹𝑎 ∶= ∑ (λ𝑝
1 + λ𝑝
2 + λ𝑝
3)𝐷𝑝,𝑎𝑝∈𝑃𝑇𝑉 + ∑ 𝜋𝑝𝐷𝑝,𝑎𝑝∈𝑆ℎ𝑒𝑙𝑙 + ∑ (μ𝑝 + τ𝑝)𝐷𝑝,𝑎𝑝∈𝑂𝐴𝑅 > 𝑐𝑎   (4.3.2) 
This inequality can be interpreted that an aperture can be priced out if the total dose gain 
in PTV voxels outperforms the total dose loss of Shell and OAR voxels by 𝑐𝑎. Therefore, 
adding this aperture will either increase PTV dose without violating OAR/Shell dose 




Like other column generation algorithms, we solve the pricing problem for each beam 
separately. Each beam is uniquely defined by its position, up vector and target point 
(isocenter) and is discretized into beamlets with certain resolution. Since each voxel is 
uniquely projected to a beamlet 𝑖 of beam 𝑏, we can re-arrange 𝐹𝑎 = ∑ 𝐹𝑖
𝑎
𝑖∈𝑏   , where 
𝐹𝑖
𝑎 ∶= ∑ (λ𝑝
1 + λ𝑝
2 + λ𝑝
3)𝐷𝑝,𝑎𝑝∈𝑃𝑇𝑉∩{𝑖} + ∑ 𝜋𝑝𝐷𝑝,𝑎𝑝∈𝑆ℎ𝑒𝑙𝑙∩{𝑖} + ∑ (μ𝑝 + τ𝑝)𝐷𝑝,𝑎𝑝∈𝑂𝐴𝑅∩{𝑖}   (4.3.3) 
Here 𝑃𝑇𝑉 ∩ {𝑖} , 𝑆ℎ𝑒𝑙𝑙 ∩ {𝑖}  or 𝑂𝐴𝑅 ∩ {𝑖}  are the set of PTV, Shell or OAR voxels 
projected to beamlet 𝑖 in the MLC plane. Recall that  𝐷𝑝,𝑎 is the dose deposited by  aperture 
𝑎 to voxel 𝑝, which is not the beamlet dose 𝐷𝑝,𝑖. As a result, the size of beamlets can be 
different in different parts of the beam to fully take advantage of the flexibility of MLC. 
For example, higher resolution can be applied to the area where PTV voxels are projected 
and lower resolution to the other area. Though the exact value of 𝐷𝑝,𝑎  is unknown 
currently, it has the following properties: 1) 𝐷𝑝,𝑎 > 0 for all voxels 𝑝 and 2) 𝐷𝑝1,𝑎 ≥ 𝐷𝑝2,𝑎 
if the distance between 𝑝1 and beam is shorter than the distance between 𝑝2 and 
beam[127]. In other word, 𝐷𝑝,𝑎 is a non-negative function and attenuate with the distance. 
Define 𝐷𝑢𝑎𝑙𝑆𝑢𝑚𝑖 = ∑ (λ𝑝
1 + λ𝑝
2 + λ𝑝
3 + 𝜋𝑝 + μ𝑝 + τ𝑝)𝑝∈𝑉∩{𝑖}  as the sum of dual 
variables of the voxels in 𝑉 that are projected to beamlet 𝑖. We can classify the beamlets 
into 5 groups: 
• G1: Only PTV voxels are projected onto beamlet 𝑖 and 𝜆𝑝
3 = 0, ∀𝑝 ∈ 𝑃𝑇𝑉 ∩ {𝑖}. 
Then 𝐹𝑖
𝑎 = ∑ (𝜆𝑝
1 + 𝜆𝑝
2 )𝐷𝑝,𝑎𝑝∈𝑃𝑇𝑉∩{𝑖} ≥ 0 ⟺ 𝐷𝑢𝑎𝑙𝑆𝑢𝑚𝑖 = ∑ (𝜆𝑝
1 +𝑝∈𝑃𝑇𝑉∩{𝑖}
𝜆𝑝




• G2: Both PTV voxels and OAR/Shell voxels are projected onto beamlet 𝑖 and 𝜆𝑝
3 =
0, ∀𝑝 ∈ 𝑃𝑇𝑉 ∩ {𝑖}. All OAR/Shell voxels are located farther to the beam than PTV 
voxels. Then 𝐹𝑖
𝑎 = ∑ (𝜆𝑝
1 + 𝜆𝑝
2 )𝐷𝑝,𝑎𝑝∈𝑃𝑇𝑉∩{𝑖} + ∑ 𝜋𝑝𝐷𝑝,𝑎𝑝∈𝑆ℎ𝑒𝑙𝑙∩{𝑖} +













3 + 𝜋𝑝 + μ𝑝 + τ𝑝)𝑝∈𝑉∩{𝑖} ≥ 0 ⟹ 𝐹𝑖
𝑎 ≥ 0. 
• G3: PTV voxels are projected onto beamlet 𝑖  and 𝜆𝑝
1 = 𝜆𝑝
2 = 𝜆𝑝
3 = 𝜋𝑝 = μ𝑝 =
τ𝑝 = 0, then 𝐹𝑖
𝑎 = 𝐷𝑢𝑎𝑙𝑆𝑢𝑚𝑖 = 0.   
• G4: PTV voxels are projected onto beamlet 𝑖 and ∃p ∈ 𝑃𝑇𝑉 ∩ 𝑖, 𝑠. 𝑡. 𝜆𝑝
3 < 0. Then 
𝐹𝑖
𝑎 = ∑ (𝜆𝑝
1 + 𝜆𝑝
2 + 𝜆𝑝




3)𝑝∈𝑉∩{𝑖} ≥ 0. 
• G5: Both PTV voxels and OAR/Shell voxels are projected onto beamlet 𝑖 but some 
OAR/Shell voxels located closer to the beam than PTV voxels. If any one of 𝜋𝑝, 
μ𝑝 , τ𝑝  is nonzero, then 𝐹𝑖




3 + 𝜋𝑝 + μ𝑝 + τ𝑝)𝑝∈𝑉∩{𝑖} ≥ 0. 
• G6: Only OAR/Shell voxels are projected onto beamlet 𝑖 . Then 𝐹𝑖
𝑎 =
∑ 𝜋𝑝𝐷𝑝,𝑎𝑝∈𝑆ℎ𝑒𝑙𝑙∩{𝑖} + ∑ (𝜇𝑝 + 𝜏𝑝)𝐷𝑝,𝑎𝑝∈𝑂𝐴𝑅∩{𝑖} ≤ 0. 
For beamlet 𝑖 in G1, G2 and G3, 𝐷𝑢𝑎𝑙𝑆𝑢𝑚𝑖 ≥ 0 implies 𝐹𝑖
𝑎 ≥ 0 and this relationship is 
independent of the shape and dose of aperture 𝑎 . Therefore, beamlets in G1-G3 with 
𝐷𝑢𝑎𝑙𝑆𝑢𝑚𝑖 ≥ 0 are of top priority to create new apertures. For beamlet 𝑖 in G4 and G5, 
𝐷𝑢𝑎𝑙𝑆𝑢𝑚𝑖 ≥ 0 cannot guarantee 𝐹𝑖




However, the inclusion of G4 and G5 beamlets enlarges the search space of new apertures 
and is useful to create large apertures. Since G5 beamlets will always reduce the value of 
𝐹𝑎, these beamlets should never be used for aperture generation. 
Since we do not know 𝐷𝑝,𝑎, finding the aperture with the largest 𝐹
𝑎 is impossible for the 
pricing problem. Since 𝑐𝑎 = 0  in all optimizations in LLDAO except the step of 
minimizing total MU, where 𝑐𝑎 = 1, the pricing problem ends up with finding an aperture 
𝑎 such that 𝐹𝑎 is as large as possible. From the previous discussion, we know that apertures 
with 𝐷𝑢𝑎𝑙𝑆𝑢𝑚𝑎 = ∑ 𝐷𝑢𝑎𝑙𝑆𝑢𝑚𝑖∈𝑎 𝑖 ≥ 0  are of high possibility to have 𝐹
𝑎 > 𝑐𝑎 . Once 
these apertures are generated, their reduced costs will be checked the same time while their 
associated   dose is calculated. Finally, apertures with 𝐹𝑎 > 𝑐𝑎 (𝑅(𝑎) < 0) will be priced 
out. Based on our experiment, this heuristic algorithm can efficiently create a large set of 
apertures with 𝐹𝑎 > 𝑐𝑎  at each iteration even though no dose information is used to 
generate these apertures. In addition, we observed that it is not necessary to eliminate 
apertures with 𝐹𝑎 < 𝑐𝑎. Although they cannot be entered into basis at current step of the 
master problem, they may become basis in later steps. So, this aperture generation 
algorithm can accelerate the optimization of master problem by generating promising 
apertures that can be included in further steps. 
Now we will explain how to generate apertures with 𝐷𝑢𝑎𝑙𝑆𝑢𝑚𝑎 ≥ 0 from dual variables. 
First, a dual sum map(DSM), which is similar to fluence map, is created for each beam. 
Beams are discretized into beamlets with certain resolution. As each voxel is uniquely 








from DSM such that 𝐷𝐹𝑀𝑖 = 1 if beamlet 𝑖 is used to create new apertures and 𝐷𝐹𝑀𝑖 =
0 otherwise. Since 𝐷𝑆𝑀𝑖 < 0 means that at least one voxel in 𝑉 ∩ {𝑖} reaches the dose 
upper bound, new apertures should avoid directly shooting on these voxels. Hence 
𝐷𝐹𝑀𝑖 = 0 for all beamlets 𝑖 with 𝐷𝑆𝑀𝑖 < 0. By considering the dose scattering effect, 
beamlets that are close to these negative 𝐷𝑢𝑎𝑙𝑆𝑢𝑚 beamlets may not be used either. Let ix 
and iy be the x and y coordinates of beamlet 𝑖 ∈ b and define 𝐸𝑖
− ≔ {𝑗 ∈ 𝑏 | 𝑖𝑥 − 𝑑− ≤
 𝑗𝑥 ≤ 𝑖𝑥 + 𝑑−, 𝑖𝑦 − 𝑑− ≤  𝑗𝑦 ≤ 𝑖𝑦 + 𝑑−, 𝑑− ∈ 𝑁
+} as the set of beamlets within 𝑑−  of 
beamlets 𝑖. Then 𝐷𝐹𝑀𝑖 = 0, ∀i ∈ {j ∈ b | j ∈ Ei
−, DSMi < 0}. For the remaining beamlets, 
𝐷𝐹𝑀𝑖 = 1  if 𝐷𝑆𝑀𝑖 > 0 . If  𝐷𝑆𝑀𝑖 = 𝐷𝑢𝑎𝑙𝑆𝑢𝑚𝑖 = 0  and 𝑖 ∈ G3 , we can include  𝑖  in 
aperture 𝑎 without changing the value of 𝐷𝑢𝑎𝑙𝑆𝑢𝑚𝑎, but can potentially make 𝑎 bigger 
and more regular. Similarly, define 𝐸𝑖
+ ≔ {𝑗 ∈ 𝑏 | 𝑖𝑥 − 𝑑+ ≤  𝑗𝑥 ≤ 𝑖𝑥 + 𝑑+, 𝑖𝑦 − 𝑑+ ≤
 𝑗𝑦 ≤ 𝑖𝑦 + 𝑑+, d+ ∈ 𝑁
+} and 𝐷𝐹𝑀𝑖 = 1, ∀i ∈ {j ∈ b | j ∈ Ei
+ ∩ 𝐺3, DSMi > 0}. Both 𝑑− 
and 𝑑+ are dilation parameters that control the shape of apertures. Larger 𝑑− will lead to 
larger 𝐹𝑎 but smaller shape while larger 𝑑+ will lead to smaller 𝐹
𝑎 but larger shape. An 
example of the whole process is shown in fig. 4.10a – fig. 4.10d. 
Once DFM is created, we can treat it as a fluence map and run leaf sequencing algorithms 
to generate apertures. For each aperture 𝑎 obtained, we have  
𝐷𝑢𝑎𝑙𝑆𝑢𝑚𝑎 = ∑ 𝐷𝐹𝑀𝑖 ×  𝐷𝑢𝑎𝑙𝑆𝑢𝑚𝑖𝑖∈𝑎 = ∑ 𝐷𝑢𝑎𝑙𝑆𝑢𝑚𝑖𝑖∈𝑎,𝐷𝐹𝑀𝑖=1 ≥ 0  (4.3.4) 
Since DFM has only one intensity level, leaf sequencing on DFM will be significantly 
simplified. Common MLC constraints are considered such as row continuity, 
interdigitation. In this study, Siochi’s algorithm[108] are implemented to generate such 




are also included: (1) minimum aperture area is 57.75mm2; (2) minimum leaf opening is 
5mm; (3) the opening must be at least 2 leaves wide at any position along the leaf moving 
direction of MLC. The final constraint is on the regularity of the aperture shape. Let Seq 
be the area of the equivalent square of an aperture and Ssa be the area of the aperture. Then 
√Seq/Ssa should be greater than 0.57. After apertures are generated by Siochi’s algorithm, 
we changed the shape of each aperture to satisfy these constraints. Basically, if a leaf’s 
opening is less than 5mm, this leaf will be closed to satisfy constraint (2). If a column has 
only one leaf open, that column will be closed either to satisfy constraint (3). Constraint 
(1) and the shape regularization constraint will be checked, and failed apertures will be 
directly eliminated.  
It is easy to see that both the Siochi’s algorithm and the additional checking procedure runs 
in polynomial time of the dimension of the DFM. Also, beamlet dose calculation is 
replaced by aperture dose calculation, which is faster and more accurate. Therefore, our 
aperture generation algorithm is very efficient in terms of computational time.  
 
 






Figure 4.10b. Dual Fluence Map(DFM) with d− = 0 and d+ = 2, red lines enclose beamlets with 
DSMi > 0, blue lines enclose beamlets with DSMi < 0 and green lines encloses beamlets with 
DSMi = 0 and within d+ of beamlets with DSMi > 0. 
 
 
Figure 4.10c. An aperture(shaded) created by running Siochi’s leaf sequencing algorithm.  
  
 
Figure 4.10d. Final Aperture(shaded) with shape corrected to satisfy MLC constraints. After dose 





4.2.4 Beam Selection 
Both fluence map optimization and direct aperture optimization often assume that a set of 
beam angles are pre-selected before the optimization. These beam angles are either chosen 
manually by planners or obtained by a heuristic algorithm combining geometry and 
intensity information. As the beam selection problem is in nature coupled with fluence map 
optimization, a combining model will outperform models solving these two problems 
separately. For example, there are mixed-integer models that simultaneously optimize 
beam angles and fluence pattern and produce global optimal solution of the beam selection 
and beam profile[96]. However, it usually takes longer time to solve than heuristic 
approaches, especially when the candidate beam angle set is large[97]. But the plan quality 
has proven to be superior[96, 98]. For direct aperture optimization, iterative algorithms are 
proposed to add beam angles greedily based on the first-order information[128]. These 
methods can return solution quickly but cannot guarantee global optimality of the selected 
beam angles.  
In this thesis, we propose a mixed-integer model that couples the beam selection and direct 
aperture optimization together. This model, similar to [96], uses binary variable to indicate 
the selection of a beam angle and constrains on the maximum number of beam angles 
allowed. However, instead of beamlet weights, aperture weights are optimized. The general 
form of the model can be formulated as 
(DAO+BS)           Min      𝐹(𝒙)                              (4.4.1) 




                   𝑥𝑎 ≤ 𝑀𝑎𝑥𝑀𝑈 𝑧𝑖,         ∀𝑎 ∈ 𝐴𝑖,  ∀𝑖 ∈ 𝐵     (4.4.3) 
        ∑ 𝑧𝑖𝑖∈𝐵 ≤ 𝐵𝑚𝑎𝑥,         (4.4.4) 
                                      𝑥𝑎 ≥  0, 𝑧𝑖 ∈ {0,1}        ∀𝑎 ∈ 𝐴𝑖 ,  ∀𝑖 ∈ 𝐵             (4.4.5) 
where 𝐷 is the set of aperture weight satisfying dose constraints on target and OARs. 𝐴𝑖 is 
the set of apertures of beam 𝑖 ∈ 𝐵 and 𝐵𝑚𝑎𝑥 is the maximum number of beams allowed. 
Compared to beamlet FMO models in which the total number of beamlets is finite and 
known before optimization, DAO models have potentially infinite number of apertures and 
can only obtain a small set of them by column generation. Therefore, to make DAO+BS 
viable, we need to generate enough aperture shapes for each beam. As the column 
generation algorithm cannot be directly used to solve DAO+BS, we first solve the DAO 
with (4.4.2) and all beam angles included. By using the column generation algorithm 
proposed in 4.2.3, each beam will have many apertures generated and the objective 
function 𝐹(𝒙) will be minimized at the same time. Then constraints (4.4.3) - (4.4.5) are 
added to select at most 𝐵𝑚𝑎𝑥 angles with the minimum objective value. Since the number 
of apertures generated in DAO is typically much smaller than the number of beamlets in 
FMO, each node in the branch-and-bound tree will be solved faster. Moreover, the optimal 
solution of DAO+BS, once obtained, is guaranteed the global optimal given the aperture 





Figure 4.11. Process map of LLDAO with beam selection. Beam selection is performed after one 
of the steps of LLDAO. Once beams are selected, later optimization will be restricted on the 
selected beams and new apertures will only be generated from the selected beams. 
 
This beam selection model serves as a module in the LLDAO model introduced in 4.2.2. 
Since different objectives in LLDAO can end up with different optimal beam selection, 
DAO+BS can be used after any step to produce a beam set that minimizes a specific 
treatment objective (fig. 4.11). For example, applying beam selection after optimizing 
conformity index will give a set of beams uniformly distributed in the 2D/3D space so that 
doses are spread out around the target to ensure good conformity. On the other hand, the 
set of beams selected after minimizing total dose of an OAR will likely avoid beams that 
directly pass through that OAR. Compared to plans with no constraints on the number of 
beams, plans with only a few beams used will likely see a compromise in the quality. To 
limit the degradation of plan quality, we first solve DAO with all beam angles included. 
Column generation is used to generate new apertures until no more apertures can be added 
to improve the objective function. Notice that solving DAO with all beams is the same as 




algorithm can successfully reduce the number of beams used without compromising much 
on the plan quality. In our experiment, the degradation of plan quality is within 5% to the 
plan with all beams. Moreover, we can further close the gap by running one more round of 
column generation to generate apertures from the selected beam angles and re-optimize the 
same objective. 
 
4.3 Computational Result  
4.3.1 Patient cases and clinical guidelines 
4.3.1.1 Prostate cases 
We first tested the efficacy of our algorithm on 5 prostate cases. Voxels are sampled using 
2×2×2mm3 for all structures. In addition to PTV and OARs, shell structures are also 
sampled to be used to optimize conformity. Each shell structure is the dilation of the surface 
of PTV by a certain distance. For prostate cases, shell structures located at 2mm, 4mm 
from PTV are used to control conformity and low dose spillage. The details of each case 
are described in Table 4.1. Treatment objectives are derived from RTOG 0938 [129] and 
are summarized in Table 4.2. The prescription dose is 36.25Gy per 5 fraction and the 
isodose should cover at least 95% of the PTV volume. The metric “D1cc < 38.06” means 






Table 4.1. Structure size of each prostate case 
Structur
es 


























PTV 8393 67.14 12419 99.35 7780 62.24 14444 115.55 9168 73.34 
Bladder 4124 32.99 7764 62.11 8056 64.45 10983 87.86 5320 42.56 
Rectum 6413 51.30 8804 70.43 7203 57.62 8160 65.28 6681 53.45 
Prostatic 
Urethra 
319 2.55 434 3.47 278 2.22 274 2.19 276 2.21 
Shell 8331 66.648 10287 82.30 8272 66.18 11191 89.53 8725 69.80 
 
Table 4.2. Treatment objectives for prostate cases (36.25Gy/5Fx) 
Structure Metric Goal (Gy) 
PTV D95% >36.25 
PTV D100% >34.4 
PTV D0% <43.5 
Rectum D1cc <38.06 
Rectum D90% <32.625 
Rectum D80% <29.00 
Rectum D50% <18.125 
Bladder D1cc <38.06 
Bladder D90% <32.625 
Bladder D50% <18.125 
Prostatic Urethra D0% <38.78 
 
4.3.1.2 Lung cases 
Lung cases are discretized using the same voxel size as prostate cases, 2×2×2mm3 for all 
structures. Moreover, shell structures located  at 2mm, 4mm and 20mm from PTV are used 
to control conformity and R50, which is the ratio of the volume of 50% of the prescription 




structure and Table 4.4 shows the treatment objectives which are derived from RTOG 0813 
[130].  
 
Table 4.3. Structure size of each lung case 
Structures 


























PTV 11215 89.72 18616 148.93 3726 29.81 11573 92.58 10177 81.42 
Spinal 
Cord 
1860 14.88 3388 27.10 1809 14.47 1387 11.10 2469 19.75 
Esophagu
s 
1301 10.41 4015 32.12 1472 11.78 1936 15.49 2643 21.14 
Heart1 60572 484.58 -- -- -- -- 8690 69.52 -- -- 
Trachea 1272 10.18 1404 11.23 1629 13.03 463 3.70 2961 23.69 
Proximal 
Bronchus 
505 4.04 331 2.65 460 3.68 812 6.50 458 3.66 
Lung 488938 3911.50 559039 4472.31 291112 2328.90 363402 2907.22 420691 3365.53 
Vessels -- -- 19338 154.70 -- -- -- -- -- -- 
Brachial 
Plexus 
-- -- 1956 15.65 -- -- -- -- 3694 29.55 
Shell 10369 82.95 17206 137.65 5490 43.92 10241 81.93 9205 73.64 
1. “--” means that such structure is not delineated in the DICOM and is not considered in the 
treatment planning optimization of that case. 
 
Table 4.4. Treatment objectives for Lung cases (50Gy/5Fx) 
Structure Metric Goal (Gy) 
PTV D95% >50 
PTV D99% >45 
PTV D0% <62.5 
Cord D0% <30 
Cord D0.25cc <22.5 
Cord D0.5cc <13.5 
Lung D1500cc <12.5 
Lung D1000cc <13.5 
Esophagus D0% <52.5 




Table 4.4 continued  
Heart D0% <52.5 
Heart D15cc <32 
Trachea D0% <52.5 







Brachial Plexus D0% <32 
Brachial Plexus D3cc <30 
vessels D0% <52.5 
vessels D10cc <47 
 
4.3.1.3 Intracranial cases 
We also tested our algorithm on 5 intracranial cases, including a schwannoma case, a 
pituitary case, two meningioma cases and a brain metastases case. Since the tumors in some 
cases are very tiny, the voxel size is set to be 1×1×1mm3. Each case has unique clinical 
objectives and the details are shown in Table 4.5 - 4.9. 








PTV D100% >11 
Brainstem 37204 37.20 D0% <12.5 
Facialis 728 0.73 D0% <15 
CAI 14 0.01 D0% <14 
Trigeminus 514 5.14 D0% <15 
Left Eye 8570 8.57 D0% <0.5 
Left Optic Nerve 1365 1.37 D0% <1 
Right Eye 8714 8.71 D0% <0.5 
Right Optic Nerve 1532 1.53 D0% <1 
Pituitary 336 0.34 D0% <1 
Optic Chiasm 1512 1.51 D0% <1 





Table 4.6. Structure size and treatment objectives for Intracranial 2 (25Gy/5Fx) 




PTV D0% <42 
Brainstem 33748 33.75 D0% <12 
Left Eye 10234 10.23 D0% <2 
Left Optic 
Nerve 
492 4.92 D0% <13.5 
Right Eye 10274 10.27 D0% <2 
Right Optic 
Nerve 
756 7.56 D0% <13.5 
Mandible 46280 46.28 D0% <5 
Optic 
Chiasm 
139 0.14 D0% <12 
                      1. The voxel size is 1×1×1mm3. 
 









PTV 3265 26.12 D95% >25 
Left Eye 846 6.77 D0% <2 
Right Eye 882 7.06 D0% <2 
Brainstem 2634 21.07 D0% <35 
Optic System 247 1.98 D0% <18 
Whole brain 201813 1614.5 D20cc <12 
  












PTV D0% <62.5 
Left Eye 952 7.62 D0% <2 
Right Eye 994 7.95 D0% <2 
Brainstem 2906 23.25 D0% <17.5 
Left Optic Nerve 168 1.34 
D0% <25.5 
D0.25cc <15 
Right Optic Nerve 122 0.98 
D0% <25.5 
D0.25cc <15 
Optic Chiasm 64 0.51 
D0% <25.5 
D0.25cc <15 
Spinal cord 292 2.34 D0% <12.5 








Size (cm3) Metric Goal (Gy) 
GTV1 539 0.539 D95% >20 
GTV2 408 0.408 D95% >20 
GTV3 74 0.074 D95% >20 
GTV4 2787 2.79 D95% >20 
GTV5 129 0.129 D95% >20 
Brainstem 25666 25.67 D0.3cc <12 
Whole brain 1196182 1196.18 
D30cc <10 
D20cc <12 
Left Optic Nerve 326 3.26 D0.2cc <8 
Right Optic Nerve 326 3.26 D0.2cc <8 
Left Hippocampus 1986 1.86 mean <3 
Right Hippocampus 2435 2.44 mean <3 
Optic Chiasm 331 0.33 D0% <8 
Left Lens 151 1.51 D0% <2 
Right Lens 175 1.75 D0% <2 
Left Eye 8892 8.89 D0% <8 
Right Eye 9050 9.05 D0% <8 
             1. The voxel size is 1×1×1mm3.  
 
For all 15 cases, by considering the delivery of radiation in real practice, the minimum MU 
of an aperture is set to be 10 MU per fraction and the maximum MU is set to be 200 MU 
per fraction. The total MU is an objective which will be minimized in the LLDAO. 
 
4.3.2 Beams and initial apertures 
Candidate beams are created using the node position in body/head paths implemented in 
the CyberKnife system. Beams are non-coplanar and uniquely determined by the node 
position from which the beams are delivered, up vector of the LINAC and target 
position/isocenter (fig. 4.12). Moreover, beams that directly pass through a critical organ 




additional preprocessing procedure often makes the planning more difficult, it benefits the 
patients in real practice by further reducing radiation to normal tissues. The multi-leaf 
collimator consists of 26 leaf pairs with each of width 3.85mm. Leaves move in the 
direction that are perpendicular to both the up vector and the direction from the node 
position to the target position. In this study, we generated the beamlets of size 3.85×2mm2 
for all prostate and lung cases and 3.85×1mm2 for intracranial cases. The number and 
location of isocenters are decided by the isocenter selection algorithm introduced in section 
4.2.1. The average solution time for solving the isocenter problem is 41.73 seconds for 
lung cases and 24.34 seconds for intracranial cases. 
 
 
Figure 4.12. Candidate non-coplanar beams in CT space. There are 171 node positions (dot) with 
1 isocenter (red circle) 
 
To start the LLDAO, we generated a set of initial apertures for each beam from the 
projection of PTV onto the MLC plane, which is spanned by the up vector and the leaf 
motion direction. For each beam, apertures will be generated from beamlets where PTV 




locate closer to the beam than PTV voxels, projected into it. Fig. 4.13 shows an example 
of creating initial apertures from this procedure. Often multiple apertures will be created if 
the projection is of irregular shape or disconnected. Moreover, aperture shapes are 
corrected to satisfy delivery constraints on MLC, such as row continuity, interdigitation. 
Apertures with area smaller than the minimum requirement will be discarded. Details of 
each case are summarized in Table 4.10. 
Table 4.10. Size of beam and initial aperture set 
Case # of isocenters # of beams1 # of initial apertures 
Prostate 1 1 62 63 
Prostate 2 1 67 67 
Prostate 3 1 76 76 
Prostate 4 1 49 49 
Prostate 5 1 59 59 
Lung 1 2 134 134 
Lung 2 3 191 285 
Lung 3 1 83 83 
Lung 4 2 173 175 
Lung 5 2 141 155 
Intracranial 1 2 211 187 
Intracranial 2 3 436 474 
Intracranial 3 2 289 303 
Intracranial 4 1 140 141 
Intracranial 5 5 675 1142 
             1. The number of beams after preprocessing 
 
  




4.3.3 Optimization result 
Based on the clinical objectives of each case, 4 main steps are implemented in the LLDAO 
to generate the treatment plan. The first step is to satisfy PTV minimum dose level and 
coverage requirements. All beam angles will be included in the optimization. Step 2 of 
LLDAO optimizes conformity index by minimizing dose to shell structures. Beam angle 
optimization will also be implemented to select a subset of beam angles out of the whole 
candidate beam set. In step 3, dose to OARs will be minimized. The order of each OAR 
added into LLDAO is based on the number of voxels that are close to the target. The last 
step is to minimize total MU of the plan. There are two considerations of optimizing 
conformity and beam selection in step 2. First, plans obtained after this step have rapid 
dose fall-off outside PTV, which means little dose will be deposited to surrounding OARs. 
Therefore, it will be easy to optimize the dose of OARs in the following steps. Second, 
based on our experiment, beam selection plays a critical role in optimizing conformity. The 
conformity index of a plan with poor beam selection can be much worse than one with 
good beam selection. And such difference cannot be decreased by simply generating new 
apertures. Therefore, we optimize beam selection in this step to obtain a set of beams with 
good (small) conformity index. Moreover, with beam selected in step 2, we only need to 
generate new apertures from the selected beam angles in the following steps so that the 
computation time can be saved. 
When optimizing each step in LLDAO, new apertures will be generated if the current 
objective does not satisfy the clinical requirement. However, objectives that do not have a 
specific clinical requirement (e.g. conformity index, total MU) will be optimized until no 




finished, the objective function will be put into constraints in the next step and will be 
constrained by the optimal objective value relaxed by 1%. Fig. 4.14a – Fig. 4.14g shows 
the progress of plan quality during LLDAO for prostate 1. Starting with the initial aperture 
set and the entire candidate beam set, minimum dose requirement and 95% prescription 
dose coverage of PTV are first satisfied respectively. By ensuring PTV requirements, dose 
to shell structures are then minimized to reduce conformity index. Clearly more beams and 
apertures are needed in this step to spread out radiation around the target.  
 
 





Figure 4.14b. Maximize lower 5% CVaR of PTV dose distribution to ensure 95% of PTV voxels 









Figure 4.14d. Minimize dose to Shell_2mm with only 20 beams allowed to be selected. 
 
 





Figure 4.14f. Minimize mean dose of rectum using 20 beams selected by beam angle optimization.  
 
 






Beam angle optimization is performed to select a set of beams with the minimum dose to 
shell structures given the aperture set generated until this step. Since mixed-integer 
program usually takes a long time to reach optimal, the first intermediate feasible solution 
obtained with optimality gap less than 1% will be selected. Compared to the plan with no 
limit on the number of beams used, plans after beam selection have a slight increase in 
conformity index. Table 4.11 summarizes the change of conformity index when the 
maximum number of beams allowed, 𝐵𝑚𝑎𝑥 , is constrained. For most of the cases, the 
degradation of conformity, due to beam selection, is less than 5%. Moreover, conformity 
improves as 𝐵𝑚𝑎𝑥 increases. It shows that the beam angle optimization model, with enough 
apertures generated by the column generation algorithm, effectively reduces the number of 
beams used while maintaining the quality of the plan.  
 
Table 4.11. Conformity index(CI) of the plan after beam selection with different 𝐵𝑚𝑎𝑥  
Case 

















Prostate 1 1.109 1.85 1.104 1.34 1.098 0.82 -- -- -- -- 1.089 
Prostate 2 1.111 3.29 1.104 2.56 1.091 1.42 -- -- -- -- 1.076 
Prostate 3 1.089 1.23 1.085 0.85 1.080 0.38 -- -- -- -- 1.076 
Prostate 4 1.104 1.56 1.098 0.98 1.094 0.63 -- -- -- -- 1.087 
Prostate 5 1.108 2.91 1.109 2.94 1.108 2.86 -- -- -- -- 1.077 
Lung 1 1.032 1.02 1.029 0.73 1.028 0.67 -- -- -- -- 1.021 
Lung 2 1.154 8.34 1.137 6.82 1.130 6.17 -- -- -- -- 1.065 
Lung 3 1.089 3.49 1.074 2.1 1.064 1.1 -- -- -- -- 1.052 
Lung 4 1.071 2.69 1.069 2.57 1.061 1.78 -- -- -- -- 1.042 
Lung 5 1.091 3.78 1.068 1.54 1.066 1.37 -- -- -- -- 1.051 
Intracranial 
1 
-- -- -- -- 1.143 4.15 1.143 4.15 1.143 4.15 1.097 
Intracranial 
2 
-- -- -- -- 1.191 1.17 1.183 0.44 1.179 0.11 1.177 
Intracranial 
3 
-- -- -- -- 1.095 0.18 1.096 0.31 1.095 0.16 1.093 
Intracranial 
4 
-- -- -- -- 1.231 4.13 1.205 1.92 1.185 0.29 1.182 
Intracranial 
5 




After beam selection, doses to OARs are minimized to satisfy the dose-volume constraints. 
For structures with large number of voxels, we divide the whole structure into several small 
parts based on the distance to the target. Parts close to the target will be first added to the 
optimization since the dose to these parts are higher than those far away from the target. 
This procedure prevents the size of the optimization from being too large and reduces the 
solution time. The last step of LLDAO is to minimize total MU of the plan. By generating 
new apertures, we can reduce the total MU while maintaining the quality of the plan (fig. 
4.14(g)). Moreover, the mixed-integer program (step 5’ in section 2.3) will be solved to 
ensure that all selected apertures will be at least 10 MU per fraction. The plan quality of 
the final solutions is shown in Table 4.12-4.18. 
 
Table 4.12. Plan quality of the optimal solution for 5 prostate cases 
Structure Metric Goal (Gy) Prostate 1 Prostate 2 Prostate 3 Prostate 4 Prostate 5 
PTV D95% >36.25 36.57 36.56 36.63 36.64 36.61 
PTV D100% >34.4 34.40 34.40 34.40 34.40 34.40 
PTV D0% <43.5 43.15 43.28 41.74 43.50 42.99 
Rectum D1cc <38.06 35.66 35.68 35.53 35.32 35.65 
Rectum D90% <32.625 29.65 28.35 26.87 29.42 31.07 
Rectum D80% <29.00 20.25 18.73 16.04 21.50 24.10 
Rectum D50% <18.125 6.89 5.41 2.43 5.37 6.01 
Bladder D1cc <38.06 34.52 34.67 30.32 35.58 35.58 
Bladder D90% <32.625 30.93 28.28 14.25 29.18 32.21 
Bladder D50% <18.125 11.94 11.11 2.69 12.95 16.34 
Prostatic Urethra 
D0% 
<38.78 38.78 38.78 38.78 38.78 38.78 
Conformity Index  1.12 1.12 1.12 1.12 1.12 
# of beams  20 20 19 20 20 
# of apertures  62 83 52 84 75 





Table 4.13. Plan quality of the optimal solution for 5 lung cases Structure Metric 
Structure Metric Goal 
(Gy) 
Lung 1 Lung 2 Lung 3 Lung 4 Lung 5 
PTV D95% >50 51.10 50.00 50.55 50.81 50.85 
PTV D99% >45 49.48 48.82 49.64 49.62 49.58 
PTV D0% <62.5 62.50 61.74 57.05 59.89 61.30 
Cord D0% <30 9.11 14.66 13.51 14.00 14.00 
Cord D0.25cc <22.5 8.21 13.04 12.15 13.58 13.65 
Cord D0.5cc <13.5 7.73 12.23 11.50 13.38 13.28 
Lung D1500cc <12.5 5.73 4.88 1.29 3.29 0.73 
Lung D1000cc <13.5 9.97 7.12 3.62 6.63 1.78 
Esophagus D0% <52.5 35.04 45.29 27.25 19.23 40.73 
Esophagus D5cc <27.5 12.44 27.50 14.71 8.71 16.01 
Heart D0% <52.5 49.10 -- -- 45.04 -- 
Heart D15cc <32 21.60 -- -- 20.96 -- 
Trachea D0% <52.5 3.58 42.22 27.60 4.18 47.22 
Trachea D4cc <18 1.14 20.85 15.81 1.14 20.30 
Proximal bronchus 
D0% 
<52.5 48.13 32.78 33.79 50.12 7.76 
Proximal bronchus 
D4cc 
<18 3.72 11.83 7.89 10.14 1.50 
Brachial Plexus 
D0% 
<32 -- 29.35 -- -- 19.37 
Brachial Plexus 
D3cc 
<30 -- 14.76 -- -- 11.66 
Vessels D0% <52.5 -- 50.59 -- -- -- 
Vessels D10cc <47 -- 35.29 -- -- -- 
Conformity Index  1.09 1.08 1.09 1.09 1.09 
# of beams  21 29 18 24 22 
# of apertures  78 161 46 73 59 
Total MU  39887.60 81418.8 19901.4 36374.3 30870.6 
 
 
Table 4.14. Plan quality of the optimal solution for intracranial case 1 
Structure Metric Goal (Gy) Intracranial 1 
PTV D98% >12 12.09 
PTV D100% >11 11.67 
Brainstem D0% <12.5 12.50 
Facialis D0% <15 14.43 
CAI D0% <14 13.74 
Trigeminus D0% <15 12.41 
Left Eye D0% <0.5 0.04 
Left Optic Nerve D0% <1 0.13 
Right Eye D0% <0.5 0.07 
Right Optic Nerve D0% <1 0.63 
Pituitary D0% <1 0.20 




Table 4.14 continued   
Conformity Index  1.17 
# of beams  22 
# of apertures  29 




Table 4.15. Plan quality of the optimal solution for intracranial case 2 
Structure Metric Goal (Gy) Intracranial 2 
PTV D95% >25 25.07 
PTV D0% <42 42.00 
Brainstem D0% <12 12.00 
Left Eye D0% <2 0.61 
Left Optic Nerve D0% <13.5 13.50 
Right Eye D0% <2 1.05 
Right Optic Nerve D0% <13.5 13.50 
Mandible D0% <5 4.73 
Optic Chiasm D0% <12 12.00 
Conformity Index  1.34 
# of beams  40 
# of apertures  44 
Total MU  12650.50 
 
 
Table 4.16. Plan quality of the optimal solution for intracranial case 3 
Structure Metric Goal (Gy) Intracranial 3 
PTV D95% >25 25.16 
Left Eye D0% <2 2.00 
Right Eye D0% <2 1.88 
Brainstem D0% <35 13.60 
Optic System D0% <18 17.69 
Whole brain D20cc <12 12.65 
Conformity Index  1.06 
# of beams  30 
# of apertures  90 







Table 4.17. Plan quality of the optimal solution for intracranial case 4 
Structure Metric Goal (Gy) Intracranial 4 
PTV D95% >25 25.30 
PTV D0% <62.5 35.00 
Left Eye D0% <2 1.65 
Right Eye D0% <2 2.00 
Brainstem D0% <17.5 13.45 
Left Optic Nerve D0% <25.5 25.50 
Left Optic Nerve D0.25cc <15 7.12 
Right Optic Nerve D0% <25.5 24.65 
Right Optic Nerve D0.25cc <15 10.25 
Optic Chiasm D0% <25.5 24.60 
Optic Chiasm D0.25cc <15 11.61 
Spinal cord D0% <12.5 4.40 
Whole brain D43cc <12 9.53 
Conformity Index  1.17 
# of beams  30 
# of apertures  92 
Total MU  11260.90 
 
Table 4.18. Plan quality of the optimal solution for intracranial case 5 
Structure Metric Goal (Gy) Intracranial 5 
GTV1 D95% >20 20.94 
GTV2 D95% >20 21.00 
GTV3 D95% >20 20.05 
GTV4 D95% >20 20.73 
GTV5 D95% >20 20.52 
Brainstem D0.3cc <12 4.02 
Whole brain D30cc <10 7.88 
Whole brain D20cc <12 9.27 
Left Optic Nerve 
D0.2cc 
<8 3.53 









Optic Chiasm D0% <8 2.50 
Left Lens D0% <2 0.73 
Right Lens D0% <2 0.33 
Left Eye D0% <8 6.77 
Right Eye D0% <8 3.47 
Conformity Index  1.30 
# of beams  35 
# of apertures  81 




For all prostate cases, our method produces plans satisfying all dosage criteria with good 
conformity. All cases use 20 beams (case 3 uses 19) with fewer than 85 apertures. The total 
MU is less than 18,000 for all cases. Lung cases use multiple isocenters and more beams 
than prostate cases since the tumor is larger and more irregular. Except for the violation of 
“trachea D4cc” for case 2 and case 5, all other dosage criteria are satisfied. Lung case 2 
and case 5 have trachea adjacent to PTV and we could not find a feasible plan even using 
the beamlet-based FMO method. Especially for lung case 2, which has the largest tumor 
(149cc) with all critical structures wrapping around, the plan uses 161 apertures with total 
MU of 81418.8. Finally, feasible plans for all 5 intracranial cases are generated.  
 
 
Figure 4.15. Comparison of dose conformity between one-isocenter plan (top) and two-isocenter 
plan (bottom) for intracranial case 1. PTV(blue), brainstem(green) and the 12Gy isodose 
line(yellow) is depicted in transversal, sagittal and coronal view. The conformity index of one-





Low conformity is essential for all clinical cases.  For the intracranial cases, excess 
radiation to normal brain cell is detrimental. Although brain tumors are usually tiny, their 
shapes are highly irregular and hence one-isocenter plans usually result in poor conformity. 
However, using multiple beam isocenters can effectively improve the conformity 
index[98]. The difference in conformity between single-isocenter plan and multi-isocenter 
plan is significant in fig. 4.15. By implementing the isocenter selection algorithm 
introduced in section 2.1, the two-isocenter plan makes the prescription isodose line tightly 
conform to the shape of the tumor. Compared to the one-isocenter plan with conformity 
index 1.55, the two-isocenter plan improves the conformity index to 1.17. 
As the radiotherapy planning is a multi-objective optimization, there are no optimal 
solutions that optimize each objective simultaneously. Medical physicists often generate 
multiple plans to balance between different objectives and present them for clinicians to 
select. To evaluate the quality trade-offs of the plan obtained by our LLDAO algorithm, 
we generate the efficient frontier of the optimization considering three aspects: conformity 
index, OAR dose and total MU (fig. 4.16). By ensuring prescription dose coverage, the 
weighted sum of these three objectives are optimized using direct aperture optimization 
with our column generation algorithm. Each point on the efficient frontier represents a 
pareto-optimal solution of the optimization. The pattern of the efficient frontier is quite 
similar across the 15 cases. Basically, more aperture MU is needed if we want the plan to 
have less dose to OARs and be more conformal. The solution obtained by the LLDAO 
algorithm, which is the star point in figure 15, optimizes each objective sequentially in the 




conformity index, low mean OAR dose but high total MU compared to other plans on the 
efficient frontier.  
 
 
Figure 4.16. Efficient Frontier of the multi-objective direct aperture optimization. Conformity 
index mean OAR dose (max OAR dose for intracranial cases) and total MU are x, y and z axis 
respectively. The star points are the optimal LLDAO solution 
 
Table 4.19. Computational statistics of the LLDAO+BS algorithm for 15 cases 
Case 
Optimization Aperture generation 
 

























Pros 1 1200.4 992.6 271.1 2464.1 247.0 39.0 124.3 18600.3 2627.3 
Pros 2 3625.9 4156.9 1405.3 9188.1 420.0 74.2 533.6 24899.9 9795.9 
Pros 3 1170.4 440.5 421.7 2032.6 338.0 76.5 452.7 29280.4 2561.8 
Pros 4 4411.7 6833.7 527.8 11773.2 300.0 59.3 657.4 30940.5 12489.9 
Pros 5 2505.5 12130.2 192.8 14828.5 305.0 69.6 605.5 33470.5 15503.7 
Lung 1 3912.5 6153.2 197.9 10263.6 901.0 269.2 55862.1 152965.0 66395.0 
Lung 2 99578.4 91902.0 6762.0 198242.3 2025.0 914.0 141299.2 250548.0 340455.5 
Lung 3 151.8 241.1 15.6 408.5 355.0 58.9 15982.6 120879.0 16450.0 
Lung 4 2093.0 8301.2 153.3 10547.5 972.0 288.1 93915.0 165198.0 104750.6 
Lung 5 1605.1 1521.2 103.6 3229.9 789.0 209.3 84671.9 141168.0 88111.1 
Intra 1 23.6 84.3 16.3 124.2 455.0 111.1 708.9 113379.0 944.2 
Intra 2 1237.1 2537.1 101.3 3875.5 1827.0 318.5 5557.3 84838.8 9751.3 
Intra 3 704.9 4194.9 905.1 5804.9 3135.0 391.6 267.5 11113.5 6463.9 
Intra 4 500.4 6173.8 1386.6 8060.7 1506.0 150.7 152.9 6010.1 8364.4 




The linear and mixed-integer programs in the LLDAO+BS method are solved by CPLEX® 
v12.6.3 with default parameters and the column generation is solved by MATLAB®. The 
detailed computational statistics is summarized in Table 4.19. The entire process consists 
of three parts: optimization, aperture generation and aperture-based dose calculation. There 
are two mixed-integer programs in LLDAO+BS model: beam angle optimization and total 
MU minimization with positive MU lower bound. For all cases, beam angle optimization 
takes up the majority effort in optimization. Except for lung cases, optimization takes up 
the majority of solution time. As the lateral scatter correction is needed to calculate dose 
in lung, the fast GPU accelerated dose calculation algorithm cannot be used. Therefore, 
dose calculation is much slower and takes up the majority of effort in solving the lung 
cases. We also include the time of beamlet-based dose calculation, which is needed in 
traditional FMO and DAO methods, using the same dose calculation algorithm from the 
Cyberknife. Since the number of beamlets in traditional FMO or DAO is far more than the 
number of apertures generated in our method, it takes much longer time to calculate the 
beamlet dose (even longer than the total solution time of our method). This shows that our 
method, by skipping beamlet dose calculation, is highly efficient to produce plans with 
good quality.  
We also tested the efficiency of the column generation algorithm. Let 𝑁0(𝑘) denote the 
number of new apertures generated in the 𝑘-th step of column generation. After the dose 
calculation, apertures with negative reduced cost will be added to the optimization and 
denote the number such apertures as 𝑁1(𝑘). Finally, let 𝑁2(𝑘) be the number of apertures 
used in the optimal solution of the 𝑘-th step. Then we have 𝑁0(𝑘) ≥ 𝑁1(𝑘) ≥ 𝑁2(𝑘), ∀k. 




optimization problems: maximize PTV 95% coverage for prostate case 1(left) and 
minimize total MU for lung case 1(right).  
 
 
Figure 4.17. Behavior of the column generation algorithm. Left: improving PTV 95% coverage for 
prostate case 1 with 5 steps of column generation. Right: reducing total MU for lung case 1 with 7 
steps of column generation. 
 
In both problems, as the initial aperture set greatly affects the optimization at step 0, 𝑁0 is 
small in step 1. However, it increases as the step 𝑘  increases and the objective value 
improves rapidly during these steps. As the objective value gradually converges, 𝑁0 will 
then decrease again. For improving PTV 95% coverage, we can see that 𝑁1(𝑘)/𝑁0(𝑘) 
decreases and 𝑁2(𝑘)/𝑁1(𝑘)  increases as the optimization proceeds (table 4.20). This 
means that more apertures will be used although fewer l objective-improving apertures are 
generated. For reducing total MU, however, the efficiency is worse than the previous 
problem and less predictable. Such difference originates from the column generation 
algorithm. In section 4.2.3, an aperture 𝑎 is created if its 𝐷𝑢𝑎𝑙𝑆𝑢𝑚𝑎 > 0 and then is kept 




objective function only contains dose variables (e.g. PTV 95% coverage), we have 𝑐𝑎 = 0. 
However, for the problem of minimizing total MU, we have 𝑐𝑎 = 1. Therefore, more 
apertures will be filtered out as they failed to satisfy 𝐹𝑎 > 𝑐𝑎. 
 
Table 4.20. Efficiency of the column generation algorithm 
Step 𝑘 Improve PTV 95% coverage Reduce total MU 
𝑁1(𝑘)/𝑁0(𝑘) 𝑁2(𝑘)/𝑁1(𝑘) 𝑁1(𝑘)/𝑁0(𝑘) 𝑁2(𝑘)/𝑁1(𝑘) 
𝑘 = 1 0.987013 0.171053 0.357143 0.6 
𝑘 = 2 0.909605 0.329193 0.30303 0.6 
𝑘 = 3 0.77972 0.390135 0.21875 0.571429 
𝑘 = 4 0.691176 0.531915 0.136364 0.666667 
𝑘 = 5 0.495935 0.540984 0.2 0.5 
𝑘 = 6 -- -- 0.26087 0.333333 
𝑘 = 7 -- -- 0.238095 0.2 
 
4.4 Conclusion 
In this chapter, we studied the entire optimization process of radiotherapy planning. We 
developed a multi-objective direct aperture optimization model that optimizes each 
treatment objectives sequentially based on their clinical priority[12-14]. New apertures will 
be generated until all objectives are clinically acceptable. Unlike current column generation 
algorithms used in direct aperture optimization, our algorithm does not require beamlet 
dose calculation to determine the shape of new apertures. Instead, new apertures are created 
by a heuristic algorithm that only uses dual values. After the dose is calculated using 
aperture-based dose calculation, apertures will be priced out and added to the optimization. 
This method not only skips the lengthy beamlet dose calculation but more importantly 




to improve the plan accuracy. Since multiple apertures are generated in each round of 
column generation, the optimization process converges to the optimal solution much faster 
than traditional column generation algorithm which only generate one aperture each round.   
From the result of 15 test cases, our model produces deliverable plans satisfying clinical 
requirements. Excluding two mixed-integer programs: beam angle optimization and total 
MU minimization with positive MU lower bound, each optimization takes less than 1 hour 
to solve. As we skip the beamlet dose calculation, the whole process can be solved faster 
than the models using beamlet dose approach. Moreover, plans using our method are 
deliverable and use small number of apertures. Since minimization of total MU is included 
as an objective in our model, we can directly address the trade-off between plan quality 
(dose requirement) and plan efficiency (total MU), which is not possible in the traditional 
two-step approach. Compare to the clinical plans of these patient cases, our plans are more 
conformal and expose the OAR and normal tissue to lower radiation dose.  
We also incorporated the beam angle optimization into the multi-objective direct aperture 
optimization to optimally select beam angles. This is the first model that optimize beam 
angle and aperture weight simultaneously in a direct aperture optimization framework. The 
mixed-integer model selects a small set of beams with just a little compromise on plan 
quality. Moreover, we proposed an optimization model to determine the number and 
location of the isocenters of beams. The result shows that using multiple isocenters can 





Although our heuristic column generation approach avoids the use of beamlet dose, we 
sacrifice the efficiency of generating objective-improving apertures. In some cases, the 
ratio of apertures used to the apertures generated is still low, which wastes some time on 
dose calculation and optimization. Our future research will focus on developing the column 
generation algorithm to improve the efficiency. Another research direction is to develop a 
model that optimally determine the priority of each treatment objective so that a 
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